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ABSTRACT OF THE THESIS 
 
 
 
Investigating Controlled Delivery of Biomolecules for Therapeutic and Diagnostic Applications 
 
by 
 
April Pan 
 
Master of Science in Bioengineering 
University of California, Los Angeles, 2017 
Professor Daniel T. Kamei, Chair 
 
 
This thesis focused on developing controlled delivery technologies to address both 
therapeutic and diagnostic applications. In the area of therapeutics, controlled delivery of anti-
cancer agents to tumor sites have the potential to increase efficacy and decrease toxic side effects. 
With regard to diagnostics, controlled delivery of the target molecule, as well as signal 
enhancement reagents, to a detection zone can improve detection limits and further distinguish the 
difference between the signal and the background. 
Cancer is the second leading cause of death in the United States. Though conventional 
treatments such as chemotherapy are effective, they frequently result in off-target cytotoxic effects. 
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There is thus a significant need to develop methodologies to achieve controlled delivery of 
therapeutic agents to tumor sites. To address this need, our research group has previously studied 
the transferrin (Tf) trafficking pathway, which is a promising mechanism for use in targeted cancer 
therapy due to the overexpression of transferrin receptors (TfRs) on cancerous cells. Our research 
group has developed a mathematical model of the Tf/TfR trafficking pathway to improve the 
efficiency of Tf as a drug carrier. By using diphtheria toxin (DT) as a model toxin, our laboratory 
discovered that mutating the Tf protein to change its iron release rate improves cellular association 
and efficacy of the drug. Though this was an improvement upon using wild-type Tf as the targeting 
ligand, conjugated toxins like DT are unfortunately still highly cytotoxic at off-target sites.  
In this work, we address this hurdle in cancer research by developing a mathematical model 
to predict the efficacy and selectivity of Tf conjugates that use an alternative toxin. For this 
purpose, we have chosen to study a mutant of DT, cross-reacting material 107 (CRM107). First, 
we developed a mathematical model of the Tf-DT trafficking pathway by extending our Tf/TfR 
model to include intracellular trafficking via DT and DT receptors. Using this mathematical model, 
we subsequently investigated the efficacy of several conjugates in cancer cells: DT and CRM107 
conjugated to wild-type Tf, as well as to our engineered mutant Tf proteins (K206E/R632A Tf and 
K206E/R534A Tf). We also investigated the selectivity of mutant Tf-CRM107 against non-
neoplastic cells. Through the use of our mathematical model, we predicted that (i) mutant Tf-
CRM107 exhibits a greater cytotoxicity than wild-type Tf-CRM107 against cancerous cells, (ii) 
this improvement was more drastic with CRM107 conjugates than with DT conjugates, and (iii) 
mutant Tf-CRM107 conjugates were selective against non-neoplastic cells. These predictions were 
validated with in vitro cytotoxicity experiments, demonstrating that the mutant Tf-CRM107 
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conjugate is indeed a more suitable therapeutic agent. Validation from in vitro experiments also 
confirmed that such whole-cell kinetic models can be useful in cancer therapeutic design.  
This thesis also presents the investigation of controlled biomolecule delivery for diagnostic 
applications. Specifically, this thesis investigates the diagnosis of chlamydia, the most common 
bacterial sexually transmitted infection worldwide. Because it is typically asymptomatic and 
frequently progresses to serious complications, there is a significant need to develop a rapid 
diagnostic test for improved screening. The lateral-flow immunoassay (LFA) is an inexpensive 
paper-based immunoassay that has such potential, but it is limited in sensitivity. Methodologies 
such as enzymatic signal enhancement can therefore improve the sensitivity of the LFA. However, 
these enhancement techniques require multiple user steps, and previous attempts to integrate these 
processes into the LFA in a simple format have been largely unsuccessful. There is thus a need to 
achieve precise fluidic manipulations and controlled delivery of biomolecules and reagents to 
condense multistep assays into an automated, user-friendly format. Our group has previously 
investigated aqueous two-phase systems (ATPSs) for the controlled delivery of biomolecules in 
LFAs. Specifically, our laboratory has demonstrated the novel application of ATPSs to improve 
LFAs by pre-concentrating target biomarkers and automatically delivering only the concentrated 
portion to the detection zone. Macroscopic phase separation behavior was also shown to be tunable 
by changing the 3D architectural design of the paper and subsequently the size of the leading phase.  
In this thesis, more advanced control of biomolecule delivery in paper-based 
immunoassays and subsequent improvement of LFA sensitivity are presented. We demonstrate (i) 
the investigation of ATPS to mediate automated, sequential delivery signal enhancement reagents, 
and (ii) the development of a housing to achieve fine tuning of conjugate release and fluid flow of 
the ATPS through the paper matrix. Specifically, the partitioning of a model enzyme, alkaline 
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phosphatase (ALP), and its substrates, nitroblue tetrazolium 5-bromo-4-chloro-3-idolyphosphate 
(NBT/BCIP), into opposite phases prevented premature enzymatic signal enhancement, and the 
phase separation behavior of ATPS on a paper matrix drove automated sequential delivery. 
Furthermore, the design of an acrylic housing prevented flow inconsistencies from evaporation 
and provided sufficient pressure contact to improve fluid flow for the paper-based test. An 
automated, single-step test was thus successfully developed. In the future, this biomolecule 
delivery technology can be extended to other diagnostic platforms and multistep assay systems.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vi 
The thesis of April Pan is approved.  
 
Wentai Liu 
Benjamin M. Wu 
Daniel T. Kamei, Committee Chair 
 
 
University of California, Los Angeles 
2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vii 
 
 
 
 
 
 
 
 
 
 
Dedicated to my family. 
 
 
 
 
 
 
 
 
 
 
 
 
	 viii 
Table of Contents 
1. Motivation and Background ....................................................................................................... 1	
1.1. Targeted Cancer Therapy ....................................................................................................................1	
1.1.1. Introduction: Cancer ....................................................................................................................1	
1.1.2. Current Methods of Controlled Biomolecule Delivery for Therapeutic Applications ................1	
1.2. Disease Detection ................................................................................................................................3	
1.2.1. Introduction: Chlamydia ..............................................................................................................3	
1.2.2. Lateral-Flow Immunoassay (LFA) ..............................................................................................3	
1.2.2. Current Methods of Controlled Delivery for Diagnostic Applications .......................................6	
2. Development of a Mathematical Model for Controlled Delivery of Mutant Transferrin-
CRM107 Molecule Conjugates for Targeted Cancer Therapy ....................................................... 8	
2.2	 Materials and Methods .................................................................................................................12	
2.2.1	 Mathematical model of DT/DTR intracellular trafficking ...................................................12	
2.2.2	 Mathematical model of mutant Tf-DT conjugate intracellular trafficking ..........................19	
2.2.3 Synthesis and Purification ...........................................................................................................31	
2.2.4	 Cell Culture ..........................................................................................................................32	
2.2.5 Conjugation of Recombinant Tf to CRM107 .............................................................................32	
2.2.6	 In Silico Cytotoxicity ...........................................................................................................33	
2.2.7	 In Vitro Cytotoxicity ............................................................................................................34	
2.3	 Results and Discussion ................................................................................................................36	
2.3.1 Sensitivity Analysis of the Parameters Associated with the DT/DTR Intracellular Trafficking 
Pathway ................................................................................................................................................36	
2.3.1	 Tf-DT Mathematical Model Successfully Predicts Improved Efficacy of Mutant Tf-
CRM107 Conjugates against Cancer Cells Relative to Wild-Type Tf-CRM107 Conjugates .............40	
2.3.2	 Tf-DT Mathematical Model Successfully Predicts Selectivity of Mutant Tf-CRM107 for 
Cancerous Cells Relative to Non-Neoplastic Cells .............................................................................45	
2.4	 Conclusion ...................................................................................................................................49	
3. 	 Investigation of Aqueous Two-Phase Systems (ATPS) and Development of a Housing for 
Automated Enzymatic Signal Enhancement in Paper-Based Immunoassays ............................... 51	
3.1	 Introduction ..................................................................................................................................51	
3.1.1	 Motivation and background .................................................................................................51	
3.2	 Materials and Methods .................................................................................................................54	
3.2.1	 Preparation of EOPO-salt ATPS ..........................................................................................54	
3.2.2	 Preparation of Anti-CT antibody- and Enzyme- decorated Gold Nanoprobes (anti-CT-
ALP-GNPs) ..........................................................................................................................................54	
3.2.3	 Partitioning of Enzymes and Substrates in ATPS ................................................................55	
3.2.4	 Preparation of Conjugate Pads with Dehydrated anti-CT-ALP-GNPs ................................55	
3.2.5	 Fabrication of acrylic housing .............................................................................................55	
3.2.6 Detection of CT with ATPS-mediated Delivery and Enzymatic Signal Enhancement ..............56	
3.3	 Results and Discussion ................................................................................................................57	
	 ix 
3.3.1	 Partitioning of Enzyme and Substrate into Different Phases ...............................................57	
3.3.2 	 Improved Conjugate Release and Background with Development of Acrylic Housing .....57	
3.3.3	 Automated sequential delivery of signal enhancement reagents with ATPS ......................61	
3.4 	 Conclusion ...................................................................................................................................63	
References ..................................................................................................................................... 64	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 x 
Acknowledgments 
This thesis would not be possible without the support of many individuals. First and 
foremost, I would like to thank my advisor and greatest teacher, Dr. Daniel T. Kamei. Your love 
and passion for teaching and mentorship is absolutely unparalleled, and I truly would not be the 
researcher I am today without you. I have grown so much under your guidance – not only in 
science, but also in character. Thank you for constantly challenging me and inspiring me to become 
a better individual.  
I would also like to thank my graduate student colleagues. Daniel “Brad” Bradbury, thank 
you for being a wonderful mentor. I have learned so much from you, and it was truly a pleasure to 
work with you. David Pereira, thank you for supporting me and having a great sense of humor. 
Sherine Cheung, thank you for being such a caring individual and for always giving me amazing 
advice.  
A huge thank you also goes out to the rest of the Kamei Lab family, all of whom I could 
not imagine these last two years without – Garrett, for mentoring me and for your jokes; Phuong, 
for being the first to welcome me when I first joined and for training me; Sam Cheng and Alison, 
for supporting me through difficult times; Allison, for being like a big sister to me; Chloe, for 
always challenging me; Justin and Eumene, for being the dynamic duo that always puts a smile on 
my face – the list goes on. Thank you all. I feel very lucky to have been able to meet and be a part 
of such an incredible group of people.  
Chapter 2 is a version of D.J. Yoon, K.Y. Chen, A.M. Lopes, A.A. Pan, J. Shiloach, A.B. 
Mason, and D.T. Kamei, “Mathematical Modeling of Mutant Tf-CRM107 Molecular Conjugates 
for Cancer Therapy.” J. Theor. Biol. 2017, 416: 88-98. Copyright © 2017 Elsevier B.V. D.T. 
Kamei was the director of research for this article. Experiments and modeling were conducted by 
	 xi 
D.J. Yoon, K.Y. Chen, A.M. Lopes, A.A. Pan, J. Shiloach, and A.B. Mason, while writing of the 
manuscript was done by D.J. Yoon, K.Y. Chen, A.M. Lopes, A.A. Pan, J. Shiloach, A.B. Mason, 
and D.T. Kamei. This work was supported by the Wallace H. Coulter Foundation Early Career 
Award and the Cancer Research Coordinating Committee grant to D.T. Kamei, by USPHS grant 
R01 DK 21739 to A.B. Mason, and by the National Council for Scientific and Technological 
Development CNPq/Brazil #234339/2014-4 to A.M. Lopes. The authors thank Drs. Robert M. 
Prins and Linda M. Liau, Department of Neurosurgery, UCLA, for kindly providing the U251cells. 
 
 
 
 
  
	 1 
1. Motivation and Background  
1.1. Targeted Cancer Therapy 
1.1.1. Introduction: Cancer 
Cancer is the second leading cause of death in the United States, with an estimation of over 
1.6 million new cases and over 600,000 deaths in 2017 alone [1]. The leading type of cancer in 
men is prostate cancer, with over 161,000 expected diagnoses in 2017, and the leading type of 
cancer in women is breast cancer, with over 252,000 expected diagnoses [1]. Although traditional 
cancer therapies such as chemotherapy have been effective in treating cancer, the cytotoxicity of 
chemotherapeutic agents results in many off-target side effects [2]. In addition, the resulting 
systemic toxicity to host cells limits the dose that can be used, which narrows the therapeutic 
window of these anticancer drugs. There is thus a significant need to develop targeted cancer 
therapies for specific treatment of cancer cells while limiting off-target side effects.  
 
1.1.2. Current Methods of Controlled Biomolecule Delivery for Therapeutic Applications  
One method of controlled delivery for targeted tumor therapy involves the use of 
monoclonal antibodies. In this approach, monoclonal antibodies that are specific to markers on 
cancer cell surfaces but not to critical normal host cell surfaces are used [3]–[5]. The specificity 
that is conferred can ideally allow the use of more potent drugs that would otherwise be too toxic 
[3]. Since monoclonal antibodies by themselves typically have low antitumor activity, these 
antibodies are conjugated to effector molecules like cytotoxic agents, immunotoxins such as the 
bacterial toxin pseudomonas exotoxin A, and radiopharmaceutical agents [4]. Ideally, the 
antibody-drug conjugate should not be active while circulating through the body, and only have 
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activity once internalized. This can be controlled with the use of an acid labile linker during the 
conjugation of the antibody to the drug. Once the antibody-drug conjugate binds to a cancer cell, 
it can be internalized via receptor mediator endocytosis. In an endosome, which has a pH of 
roughly 5, the linker is cleaved, and the active version of the drug is released [3], [4], [6]. Despite 
the promise of this method, initial results were disappointing, with modest cell killing activity, 
lack of selectivity, and low intracellular drug concentration [3], [7]. In addition, the therapeutic 
windows are hampered by toxicities related to the drug component of the antibody-drug conjugate 
[7]. Though there have been efforts to improve the use of antibody-drug conjugates, many 
challenges still remain for this method of controlled delivery [4].  
Another method for specific delivery of cancer therapeutic agents involves taking 
advantage of the enhanced permeability and retention (EPR) effect [5], [8]–[10]. This EPR effect 
describes the phenomenon in which macromolecules and small molecules in the 60-400 nm size 
range extravasate and accumulate in tumors due to the inherent leaky vasculature in cancerous 
tissues and poor lymphatic drainage [8]. The advantage of this approach is that the potential 
accumulation of nanosized agents within tumors can enhance therapeutic payloads to the sites of 
the tumors [9], [10]. Despite this accumulation, several challenges and barriers to this method still 
remain. Although the permeability and retention of the nanosized agents are enhanced, the 
improvement is only modest, with only a rough 2-fold increase in delivery compared to normal 
critical organs [9]. Thus, if the drug stays in circulation for a long time, it can also extravasate into 
normal tissues, limiting the specificity of this delivery technique. This is partially due to the fact 
that increased vessel permeability and poor lymphatic drainage also results in high interstitial fluid 
pressure in solid tumors, which decreases the convection of nanosized drugs into the tumor site 
[9]. In addition, rapid and unchecked tumor growth results in solid stress vessel compression, 
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which reduces perfusion. The reduced perfusion limits the distribution of nanosized drugs into the 
tumor site as well [9]. The combined issues with the EPR effect limits the efficacy of this delivery 
system, and thus there remains a need to develop an improved method of targeted delivery for 
cancer cells.  
 
1.2. Disease Detection 
1.2.1. Introduction: Chlamydia 
Chlamydia is the most common bacterial sexually transmitted infection worldwide [11]. 
Caused by infections of the bacteria Chlamydia trachomatis (C. trachomatis, CT), it causes 
urethritis in men and cervicitis in women [12]. Chlamydia is typically asymptomatic, and thus 
frequently progresses to complications [13]. Left untreated, the disease can progress to more severe 
health problems, such as pelvic inflammatory disease and ectopic pregnancies [12].  
Currently, chlamydia infections are diagnosed by laboratory testing such as nucleic acid 
amplification tests [11].Though these types of testing are highly accurate and have a low rate of 
false positives, they require expensive lab equipment, trained personnel, and are extremely time 
intensive, resulting in barriers to diagnosis and potential secondary transmissions [11]. There is 
thus a clinical need for developing a point-of-care (POC) device that is more accessible and rapid.  
1.2.2. Lateral-Flow Immunoassay (LFA) 
An ideal POC device would ideally satisfy the World Health Organization’s (WHO’s) 
ASSURED criteria and be affordable, sensitive, specific, user-friendly, rapid and robust, 
equipment-free, and deliverable to end users [14]. One potential assay that can satisfy some of 
these criteria is the lateral-flow immunoassay (LFA). The LFA is paper-based, inexpensive, driven 
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by capillary pressure and thus does not require vacuums or pumps, and requires little to no extra 
training [15]. 
The LFA detects for the presence or absence of a given biomarker by utilizing colorimetric 
indicators such as colloidal gold nanoparticles (GNPs) that are conjugated to an antibody specific 
for that biomarker. A typical LFA has three main components to the test: a sample pad, conjugate 
pad, detection zone, and absorbent pad (Fig 1.1a). The function of the sample application pad is 
to absorb sample fluid. As the sample fluid wicks up by capillary action, the sample fluid comes 
in contact with the conjugate pad. The conjugate pad contains dehydrated GNPs, as well as 
preservation components such as sucrose or trehalose to enhance the longevity of dehydrated 
biomolecules [16]–[20]. Once the fluid front reaches the end of the conjugate pad, the conjugates 
are rehydrated, and the solution starts wicking into the middle detection zone. This detection zone 
is typically constructed of a nitrocellulose membrane material [21], [22].  
In the sandwich assay format of the LFA, antibodies against the target biomarker are 
immobilized on the membrane to constitute a test line. Secondary antibodies or immunoglobulin 
binding proteins such as Protein A are immobilized upstream to constitute a control line. As the 
sample fluid containing the target biomarker and the dehydrated GNPs are wicked up into the 
nitrocellulose detection zone region, biomarker-colloidal GNP complexes present in a positive test 
sample can bind to the test line due to antibody-binding interactions. This results in the biomarker 
being “sandwiched” between two antibodies and immobilized on the test line. As the fluid front 
continues to move, antibodies on the GNPs will interact with secondary antibodies on the control 
line and become immobilized as well, signifying a valid test. Thus, a positive test is indicated by 
the presence of two lines on a sandwich format LFA, and a negative test is indicated by the 
presence of a single line (Fig 1.2.1b). Lastly, the fluid is absorbed by the absorbent pad. 
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While commercial LFAs for chlamydia detection do exist, they often require a diluent as a 
component of the assay, which reduces the concentration of the bacteria found to a fraction of its 
original concentration [11]. The resultant low concentrations decrease the sensitivity of the assay. 
There thus remains a significant need for LFAs to be improved.  
One approach to improving the sensitivity of LFA tests is to enhance the signal to increase 
the intensity of the signal at the detection zone. Approaches such as enzymatic signal enhancement, 
silver enhancement, and gold enhancement have been studied in the literature [14], [23]–[27]. 
However, these types of methodologies require the use of multiple reagents and thus several 
precisely timed steps, which diminishes the user-friendliness of LFAs and their applicability as 
POC tests. Controlling fluid flow and precise biomolecule delivery is thus necessary to develop an 
LFA integrated with signal enhancement technology in an automated, single-step format.  
Fig 1.1 Schematic of the LFA sandwich assay. The setup of the test is shown in (a), and the test 
results as seen by the user is shown in (b).  
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1.2.2. Current Methods of Controlled Delivery for Diagnostic Applications  
Developing methods of controlled biomolecule delivery is necessary in order to implement 
more complex paper-based immunoassays. Discussed below are several attempts from the 
literature to develop methods of fluidic manipulation.   
The first class of controlled delivery methods for paper-based immunoassays requires an 
additional user step. For example, the Yager group at the University of Washington has previously 
developed a foldable paper card in which a user step of folding places components of the paper 
assay in contact with each other and initiates the test [28]. The folding paper card format can also 
be used during the test to initiate subsequent steps [24]. Another example is the use of a paper-
based slip device developed by Kwon and coworkers, in which sequential delivery was achieved 
by sliding a slip on the device [29]. Though these methods are effective, the use of an additional 
user step limits the user-friendliness of the test and strays from the WHO’s ASSURED criteria.  
Another method of controlled delivery for paper-based immunoassays involves 
manipulation of paper geometric designs. Altering dimensions of the channel such as the length 
and width of the paper strip can tune the fluid flow speed [30]. In addition, geometric designs of 
the paper test can be manipulated such that multiple flows are created to deliver reagents [28]. Yet 
another geometric approach that has been studied involves the slowing of fluid flow with a fluidic 
shunt. In this method, fluid is diverted into a parallel strip of paper, providing fluidic resistance 
[31]. Though this approach is relatively simple, it does require the use of more paper and can thus 
limit the test to only larger volume samples.   
Recently, control valves have also been fabricated for paper-based tests. A fluidic diode 
that promotes or stops wicking along a paper channel was developed by the Faghri group and 
incorporated into a fluidic circuit [32]. The group achieved flow directionality with the control 
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valve by fabricating the hydrophilic channel such that only one side surrounding a hydrophobic 
region had a dehydrated surfactant-rich region. Fluid could then only flow from the surfactant-rich 
region to the hydrophobic region. Though this approach is effective, this type of fluidic valve 
mechanism releases many surfactants, which can denature and/or affect the binding ability of the 
antibodies that are central to paper-based immunoassay technology [33].  
Another popular method of controlled delivery is the use of dissolvable barriers to slow 
down fluid flow. One approach is to dehydrate components such as sucrose onto a paper strip. 
Fluidic delays can thus be achieved through the increased time required to resolubilize the sucrose. 
In addition, the viscosity of the solution increases due to the addition of sucrose, and the fluid front 
travels more slowly in accordance with the Washburn equation [34]. Another type of dissolvable 
barrier that has been studied utilizes water soluble pullulan films [35]. The method of dissolvable 
barriers, however, results in the addition of components to the assay, which has the potential to 
interfere with antibody binding and analyte detection. 
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2. Development of a Mathematical Model for Controlled Delivery of Mutant 
Transferrin-CRM107 Molecule Conjugates for Targeted Cancer Therapy  
Cancer is the second leading cause of death in the United States, with over 1.6 million new 
cancer cases and 590,000 deaths in the country every year [36]. Though traditional treatments such 
as chemotherapy can be effective, they frequently cause dangerous side effects due to nonspecific 
off-target toxicity. One method to improve targeted drug delivery is through the use of drugs 
conjugated to transferrin (Tf). Human serum Tf is a monomeric glycoprotein with a molecular 
weight of approximately 80 kDa, which is involved in transporting iron to the cells in the body. 
Because of the overexpression of the transferrin receptor (TfR) on a variety of metastatic cells, Tf 
has been investigated as a potential targeting agent for cancer treatment [2], [37], [38]. Though Tf 
has been shown to be effective in targeting cancerous cells, its ability to delivery therapeutics is 
often limited by its inherent TfR-mediated intracellular trafficking pathway. For example, the 
entire Tf cycle has been shown to last only ~5 min in a human erythroleukemia-derived cell line 
(K562 cells), and therefore, 30 successive cycles of Tf-toxin conjugate trafficking would be needed 
before the cytotoxicity on the cell can be observed [39], [40]. Furthermore, after iron-loaded Tf 
(holo-Tf) delivers its iron payload within the cell, the iron-free Tf (apo-Tf) has significantly 
reduced binding affinity to TfR outside the cell, and therefore, is unable to re-enter the trafficking 
pathway until it can bind to free iron, which is not an efficient process [41]–[43]. While the cycle 
demonstrates evolutionary efficiency for rapidly delivering large quantities of iron to cells, this 
short duration limits the window of opportunity for Tf to deliver a cytotoxic payload. 
To identify a molecular-level design criterion to increase the time Tf spends with the cell 
(i.e., increase its cellular association) and predict trends, our laboratory previously developed a 
mathematical model of the Tf/TfR intracellular trafficking pathway based on the principles of mass 
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action kinetics [44], [45]. Through analysis of the model, our research group discovered that an 
increase in cellular association could be accomplished by inhibiting the iron delivery rate of Tf. 
We subsequently demonstrated that two engineered Tf mutants (K206E/R632A Tf and 
K206E/R534A Tf) with reduced iron release rates dramatically increased cellular association in 
HeLa and glioma cells. These Tf mutants were then conjugated to DT, and the mutant Tf-DT 
conjugates were significantly more cytotoxic than the wild-type Tf-DT conjugate when 
administered to HeLa and glioma cells [46], [47]. Though these mutant Tf conjugates with DT 
were effective against cancer cells, they cannot be utilized clinically due to the potential of DT to 
cause toxicity at off-target sites. It has been suggested that only a few micrograms of DT cause 
death in an unimmunized human [48]. In fact, our previous studies have shown that a conjugate 
concentration lower than 3.16 ´ 10-11 M will cause cell death [46]. Thus, an alternative drug to DT 
must be investigated for clinical treatment.  
In this work, we aimed to address this challenge by developing a mathematical model that 
can predict the behavior of other toxins conjugated to Tf. For this theoretical investigation of a 
novel conjugate, we chose to study a mutant of DT known as cross-reacting material 107 
(CRM107). CRM107 is identical to DT but with two point mutations that decrease its binding 
affinity to its native receptor, heparin-binding epidermal growth factor precursor (preHB-EGF), 
by 8,000 fold [49]. The reduction in binding affinity to this DT receptor (DTR) can potentially 
lower nonspecific toxicity. In addition, unlike other toxins with negligible toxic side effects, e.g., 
saporin and gelonin, CRM107 maintains the inherent membrane translocation activity of DT, 
providing CRM107 with a means of endosomal escape upon cellular internalization. By facilitating 
its localization to the cytosol, its site of action, the efficacy of the toxin following receptor-
mediated endocytosis is greatly improved. Thus, CRM107 has the potential for reducing 
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nonspecific toxicity at off-target sites while maintaining toxicity in tumor cells. Furthermore, our 
prior experience with DT allows us to translate our mutant Tf-DT conjugate formulation and 
characterization methods to CRM107.  
We modeled the Tf-toxin conjugates by extending our previous Tf/TfR trafficking model 
to include the DT/DTR trafficking pathway. Fig. 2.1 shows the transferrin-related trafficking 
parameters associated with ligand/receptor and ligand/metal interactions that we have previously 
investigated [45]. Holo-Tf first binds to its receptor on the cell surface at a rate of kFeTf,TfR, and is 
internalized at a rate of kint,Tf. The iron can then be released from the transferrin (kFe,rel), and apo-
Tf is either degraded (kdeg,Tf) or recycled to the surface (krec). To account for DT and its mutant, 
CRM107, the DT/DTR trafficking pathway (Fig 2.2) was investigated. The Tf-DT conjugates can 
enter via the DT pathway through DT binding to its native receptor (kDT) and being internalized 
(kint,DT). The catalytic domain of DT (DTA) is then separated from its receptor-binding and 
translocation domains (DTB) and translocated into the cytosol (ktrans), where the toxin kills the 
cell. The DT receptor is then degraded (kdeg(1-fDT)), where fDT is the fraction of internalized DT 
sorted for translocation. Species balances associated with this combined Tf-DT trafficking model 
can be found in the Materials and Methods section.  
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Fig. 2.1 Tf-related trafficking parameters used in the combined Tf-DT trafficking pathway. For this part of the 
pathway, holo-Tf conjugated with DT enters the cell through TfR, then internalized as a holo-Tf/TfR complex. DT can 
then be cleaved, and DTA is released into the cytosol. After iron from Tf is released, the apo-Tf/TfR complex is either 
degraded or recycled. For the recycled apo-Tf/TfR complex, the apo-Tf is released when it returns to the cell surface.  
 
 
Fig. 2.2 DT-related trafficking parameters used in the combined Tf-DT trafficking pathway. For this part of the 
pathway, Tf-DT conjugates enter the cell through binding to DTR. The Tf-DT/DTR complex is then internalized, where 
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DT can be cleaved and DTA can be translocated into the cytosol. In addition, once inside the cell, iron can be released 
from Tf, and the Tf-DT/DTR complex can be degraded.   
 
In this study, we used our mathematical model of the Tf-DT intracellular trafficking 
pathway to investigate the cytotoxicity of native Tf and our mutant Tf (K206E/R632A Tf and 
K206E/R534A Tf) conjugated to DT and CRM107. These simulations were performed to 
theoretically examine the use of mutant Tf as a targeting ligand for CRM107 and investigate the 
efficacy of those conjugates against cancer cells, as mutant Tf-CRM107 conjugates are assumed 
to only enter cells through the Tf/TfR trafficking pathway. We also used the mathematical model 
to investigate whether or not changing the toxin moiety of our Tf-based therapeutic agent to 
CRM107 actually results in selectivity against normal cells and an improved therapeutic index. 
These mathematical predictions were then validated using in vitro studies in various cancerous and 
non-cancerous cell lines.  
 
2.2 Materials and Methods 
2.2.1 Mathematical model of DT/DTR intracellular trafficking 
A DT/DTR intracellular trafficking model was derived using the principles of mass action 
kinetics and was incorporated into our previous Tf/TfR model. The assumptions for this model are 
listed below, as are the species balances associated with this extension. Model parameters are 
discussed in this section as well.   
Model Assumptions 
The behavior of this model was defined through several assumptions as described below. 
i. The total number of DTR was assumed to be constant, as an equal number of DTR 
was assumed to be synthesized by the cell as was degraded.  
	 13 
ii. The DTR is typically processed by one of two ways. It is either proteolytically 
processed into its mature soluble form, or it is internalized into the cell for 
degradation [50]. DTR turnover occurs primarily through this latter internalization 
pathway. The model assumed that the proteolytic processing of DTR is negligible. 
The model also assumed that the internalization rate was the same for free and DT-
bound DTR, since it is believed that DT enters cells by hijacking this inherent 
internalization pathway of DTR. 
iii. Internalized DTR was assumed to only follow the lysosomal degradation pathway 
upon clathrin-dependent internalization. This is supported by studies of the effects 
of protein biosynthesis inhibitors on the DT/DTR trafficking cycle. These studies 
demonstrate that inhibition of cellular protein biosynthesis prevents the recovery of 
steady-state levels of cell-surface DTR following internalization. Cell-surface 
levels of this protein are re-established to steady-state levels upon removal of the 
inhibitor, suggesting DTR must be constantly re-synthesized [51].  
iv. It was assumed that once the DT/DTR complex is internalized, DT does not 
dissociate from its receptor.  
v. It was assumed that once the catalytic domain of DT (DTA) is separated from its 
receptor-binding and translocation domains (DTB) and released into the cytosol, it 
was not inactivated or degraded within the timeframe of the model simulation. This 
is supported by experiments demonstrating that more than 80% of DTA directly 
injected into the cytosol of Ehrlich ascites tumor cells can be recovered intact 
following a 20 h incubation [52].  
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Model Equations  
Species balances were written for the DT/DTR trafficking pathway based on the model 
assumptions listed previously. Note that the model accounts for some spatial dependence by 
defining separate species based on their locations. 
Species balance for bulk extracellular DT 𝑑 𝐷𝑇$%&'𝑑𝑡 = (−𝑘-.𝐷𝑇$%&'𝐷𝑇𝑅0%12 + 𝑘-.,1𝐷𝑇_𝐷𝑇𝑅0%12) 𝑛78&&𝑉$%&'𝑁; 
Species balance for surface DTR 𝑑 𝐷𝑇𝑅0%12𝑑𝑡 = −𝑘<=>,-.𝐷𝑇𝑅0%12 − 𝑘-.𝐷𝑇$%&'𝐷𝑇𝑅0%12 + 𝑘-.,1𝐷𝑇_𝐷𝑇𝑅0%12+ 𝑘?8@𝐷𝑇_𝐷𝑇𝑅&A0 + 𝑘?8@𝐷𝑇𝑅&A0 + 𝑘?8@𝐷𝑇𝐵_𝐷𝑇𝑅&A0	 
 
Species balance for surface DT/DTR complex 𝑑(𝐷𝑇_𝐷𝑇𝑅0%12)𝑑𝑡 = 𝑘-.𝐷𝑇$%&'𝐷𝑇𝑅0%12 − 𝑘-.,1𝐷𝑇_𝐷𝑇𝑅0%12 − 𝑘<=>,-.𝐷𝑇_𝐷𝑇𝑅0%12 
Species balance for endosomal DTR 𝑑(𝐷𝑇𝑅8=)𝑑𝑡 = 𝑘<=>,-.𝐷𝑇𝑅0%12 − 𝑘&A0𝐷𝑇𝑅8= 
Species balance for endosomal DT/DTR complex 𝑑(𝐷𝑇_𝐷𝑇𝑅8=)𝑑𝑡 = 𝑘<=>,-.𝐷𝑇_𝐷𝑇𝑅0%12 − 𝑘>1D=0𝑓-.𝐷𝑇_𝐷𝑇𝑅8= − 𝑘&A0 1 − 𝑓-. 𝐷𝑇_𝐷𝑇𝑅8= 
 
Species balance for endosomal DTB/DTR complex 𝑑(𝐷𝑇𝐵_𝐷𝑇𝑅8=)𝑑𝑡 = 𝑘>1D=0𝑓-.𝐷𝑇_𝐷𝑇𝑅8= − 𝑘&A0𝐷𝑇𝐵_𝐷𝑇𝑅8= 
Species balance for lysosomal DTR 𝑑(𝐷𝑇𝑅&A0)𝑑𝑡 = 𝑘&A0𝐷𝑇𝑅8= − 𝑘?8@𝐷𝑇𝑅&A0 
 
(2.4) 
(2.5) 
(2.6) 
(2.7) 
(2.3) 
(2.1) 
(2.2) 
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Species balance for lysosomal DT/DTR complex 𝑑 𝐷𝑇_𝐷𝑇𝑅&A0𝑑𝑡 = 𝑘&A0 1 − 𝑓-. 𝐷𝑇_𝐷𝑇𝑅8= − 𝑘?8@𝐷𝑇_𝐷𝑇𝑅&A0 
 
Species balance for lysosomal DTB/DTR complex 𝑑(𝐷𝑇𝐵_𝐷𝑇𝑅&A0)𝑑𝑡 = 𝑘&A0𝐷𝑇𝐵_𝐷𝑇𝑅8= − 𝑘?8@𝐷𝑇𝐵_𝐷𝑇𝑅&A0 
Species balance for cytosolic DTA 𝑑(𝐷𝑇𝐴7A>)𝑑𝑡 = 𝑘>1D=0𝑓-.𝐷𝑇_𝐷𝑇𝑅8= 
 
Model Parameters 
While kint,DT was estimated directly from empirical data found in the literature, other 
parameters (i.e., kDT, kDT,r, ktrans, klys, kdeg) were estimated by fitting our model equations to 
experimental data found in the literature using least squares minimization. The following 
paragraphs will discuss how the model parameter values were determined. A full list of model 
parameters can be found in Table 2.1.  
The internalization rate constant kint,DT for DTR and the DT/DTR complex was determined 
from studies performed by Leppla and colleagues on Vero monkey kidney cells [53]. Vero cells 
are highly sensitive to diphtheria toxin, and have been demonstrated to express between 1 x 105 
and 2 x 105 receptors for DT [54]. Vero cells were pre-bound at 4°C with 125I-labeled DT at a 
concentration (0.3 µg/mL) that was shown to bind between 1 x 104 and 2 x 104 surface receptor 
sites. At this time, the cells were washed to remove any unbound toxin, and the cells were 
incubated at 37°C in fresh media to initiate cell surface DT/DTR complex internalization. Though 
some of the receptor-bound DT was found to dissociate from its receptor, this effect was negligible.  
 
(2.8) 
(2.9) 
(2.10) 
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These conditions allowed Eq. (2.3) to be simplified to:  𝑑(𝐷𝑇_𝐷𝑇𝑅0%12)𝑑𝑡 = −𝑘<=>,-.𝐷𝑇_𝐷𝑇𝑅0%12 
Equation (2.11) was then integrated. Applying the initial condition that the total number of 
DT/DTR complexes at t = 0 is DT_DTRsurf,0 yields:  ln 𝐷𝑇_𝐷𝑇𝑅0%12 = −𝑘<=>,-.𝑡 + ln	(𝐷𝑇_𝐷𝑇𝑅0%12,K) 
Given the half-time (t = t1/2) of DT/DTR complex internalization to be 25 min, where DT_DTRsurf 
is equal to ½ DT_DTRsurf,0, we estimated kint,DT to be 0.028 min-1 [53].  
The rate constants kDT, kDT,r, ktrans, klys, and kdeg were estimated by fitting them using our 
model equations and the experimental data for cell-mediated DT reduction, as determined by 
Montecucco and colleagues, using least squares minimization [55]. In this fitting procedure, we 
first converted the given percentage data to units of molecules/cell. Similar to the Leppla and 
colleagues study on Vero cell DT internalization, Montecucco and colleagues began their 
investigation with Vero cells pre-bound with 125I-labeled DT [53]. To attain equilibrium binding, 
Vero cells were pre-bound with DT by incubating them for 18 h with 3 × 10-9 M (DT0) of 125I-
labeled DT at 4°C, which inhibits internalization. With this information, we determined the 
equilibrium number of cell surface DT/DTR complexes (DT_DTReq), in units of molecules/cell, 
using the following definition of KD: 
𝐾- ≡ 𝐷𝑇8N𝐷𝑇𝑅8N𝐷𝑇_𝐷𝑇𝑅8N  
Here, DTeq is the equilibrium molar concentration of unbound DT, DTReq is the equilibrium 
number of cell surface receptors in units of molecules/cell, and DT_DTReq is the equilibrium 
number of cell surface complexes in units of molecules/cell. Assuming the total number of 
receptors (DTRT) does not change during this process, we can rewrite DTReq as: 𝐷𝑇𝑅8N = 𝐷𝑇𝑅. − 𝐷𝑇_𝐷𝑇𝑅8N 
(2.13) 
(2.14) 
(2.12) 
(2.11) 
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Additionally, following appropriate unit conversion, DTeq can be shown to be equal to: 
𝐷𝑇8N = 𝐷𝑇K − 𝐷𝑇_𝐷𝑇𝑅8N𝑛78&&𝑁;𝑉$%&'  
Substituting Eqs. (2.14) and (2.15) into (2.13) and simplifying, we obtain the following expression: 
𝑛78&&𝑁;𝑉$%&' 𝐷𝑇_𝐷𝑇𝑅8N O − 𝐾- + 𝑛78&&𝑁;𝑉$%&' 𝐷𝑇𝑅. + 𝐷𝑇K (𝐷𝑇_𝐷𝑇𝑅8N) + 𝐷𝑇𝑅. 𝐷𝑇K = 0 
 
The quadratic equation was used to solve for DT_DTReq. A DTRT value of 1.5 × 105 molecules/cell 
and a DT0 value of 3 × 10-9 M were used. For ncell, Vbulk, and NA, the values given in Table 2.1 
were used in the solution. With regard to KD, work by the Mekada laboratory had previously 
determined its value for the DT/DTR interaction to range from 0.7 to 3 × 10-9 M [56], [57]. As a 
first approximation for the model, the KD value of the DT/DTR interaction was estimated to be 10-
9 M. With these numbers, we evaluated the following: 
𝐷𝑇_𝐷𝑇𝑅8N = 	 2.57	×	10V𝑜𝑟	1.11	×	10Y 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠/𝑐𝑒𝑙𝑙 
However, since the larger value of DT_DTReq (2.57 ´ 106) obtained was greater than DTRT, this 
value was clearly not the solution. Therefore, the initial value of DT/DTR complexes on the cell 
surface in the Montecucco study was estimated as 1.11 × 105 molecules/cell. This initial value of 
the number of DT/DTR complexes on the cell surface corresponded to approximately the total 
number of cell-surface DT receptors, which was used to convert the percentage data in the 
Montecucco study to units of molecules/cell. The conversions were made specifically for the data 
performed at 37oC investigating the percent 125I-DT released in the medium and associated with 
cells and the percent 125I-DTA associated with cells. The data was then used to fit the kDT, kDT,r, 
ktrans, klys, and kdeg rate constants by using the DT/DTR trafficking model equations and least 
squares minimization with initial conditions set to zero for all species except DT_DTRsurf (1.11 × 
(2.15) 
(2.16) 
(2.17) 
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105 molecules/cell), and DTRsurf (3.92 × 104 molecules/cell). The model fit the experimental data 
reasonably well. Estimates for the kDT, kDTr, ktrans, klys, and kdeg rate constants were determined to 
be 1.90 × 107 M-1 min-1, 1.90 × 10-2 min-1, 1.5 × 10-1 min-1, 1.8 × 10-1 min-1, and 4.0 × 10-2 min-1, 
respectively. The fitted parameters kDT, kDT,r, klys, and kdeg were reasonably similar to literature 
values of comparable biomolecules [58], [59]. 
With regard to the association rate constant of DT for DTR, kDT, it was estimated by the 
following equality for the equilibrium dissociation constant (KD): 
𝐾- = 𝑘-.,1𝑘-.  
In this estimation, the KD value of the DT/DTR interaction was again estimated to be 10-9 M, and 
kDTr was estimated in the above fitting procedure to be 1.90 × 10-2 min-1. 
 
Rate Constant Definition Value Ref. 
kDT Association rate constant of 
DT for DTR 
1.90 ´ 107 M-1 min-1 Est. 
kDT,r Dissociation rate constant of 
DT for DTR 
1.90 ´ 10-2 min-1 Est. 
kint,DT Internalization rate constant 2.8 ´ 10-2 min-1 Est. 
ktrans Endosomal translocation rate 
constant 
1.5 ´ 10-1 min-1 Est. 
klys Endosome to lysosome rate 
constant 
1.8 ´ 10-1 min-1 Est. 
kdeg Degradation rate constant 4.0 ´ 10-2 min-1 Est. 
fDT Fraction of internalized DT 
sorted for translocation 
3.33 ´ 10-1 (Dorland et al., 1979) 
ncell Cell number 4.75 ´ 105 cells (Papini et al., 1993) 
Vbulk Bulk media volume 5 ´ 10-4 L (Papini et al., 1993) 
NA Avogadro’s number 6.02 ´ 1023 mol-1 N/A 
Table 2.1 List of parameters in the DT/DTR intracellular trafficking model. 
 
(2.18) 
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2.2.2 Mathematical model of mutant Tf-DT conjugate intracellular trafficking  
To fully model the Tf-toxin conjugates, we combined our Tf/TfR model developed 
previously with the DT/DTR trafficking model developed in Section 2.2.1 [45]. The model 
assumptions are discussed in this section, as are the relevant equations and parameters. 
 
Model Assumptions 
The model assumptions used for the development of the Tf/TfR and DT/DTR (Section 
2.2.1) trafficking models also apply to the Tf-DT trafficking model with the following changes 
and additions [45]. 
i. Direct measurements of the iron release rate within cellular endosomes, kFe,rel, are 
unavailable for both wild-type and mutant Tf. However, since iron is completely 
released from internalized wild-type Tf prior to recycling back to the cell surface, 
the same estimate of 100 min-1 as used in the Tf/TfR trafficking model was applied 
to the Tf-DT conjugate trafficking model for wild-type Tf-DT [60]. 
ii. Since kFe,rel for our mutant Tf had previously been estimated to be on the order of           
10-3 min-1, this value was assumed in the model for mutant Tf-DT conjugates [61]. 
iii. Since the binding affinity of CRM107 to preHB-EGF is 8,000-fold less than that of 
DT to preHB-EGF, kDT was lowered by 8,000-fold for CRM107 conjugates.  
iv. The vesicle/tubule partition coefficient, κ, was calculated according to the 
expression κ = (1–λ)2, where λ is the diameter of the Tf-DT conjugate divided by 
the diameter of the tubule [62]. An average Tf-DT conjugate diameter of 20 nm 
was estimated from the crystal structures of Tf and DT by summing the longest 
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length scale of each individual molecule together. A tubule diameter of 60 nm was 
assumed [63]–[65]. 
v. Endosomal Tf-DT conjugates, not associated with either receptor, were assumed to 
be unable to associate with the endosomal membrane and translocate DTA. 
vi. It was assumed that the Tf-DT conjugate was required to be associated with TfR in 
the vesicular compartment (which is destined for degradation) to be competent for 
DTA translocation into the cytosol when internalized via the Tf/TfR trafficking 
pathway. This is supported by studies demonstrating that DT membrane insertion 
and translocation requires an endosomal pH drop to ~4, while endosomal pH is not 
expected to drop below ~5.5 in the Tf/TfR recycling pathway [40], [66], [67]. 
vii. It was assumed that once the DT portion of the conjugate had associated with the 
endosomal membrane and translocated its catalytic domain into the cytosol, the 
remaining endosomal molecule was sorted for lysosomal degradation through the 
DT/DTR trafficking pathway irrespective of the receptor the conjugate was 
associated with. 
 
Model Equations 
The full list of all species and parameters, as well as the species balances associated with 
the Tf-DT conjugate intracellular trafficking model, can be found below. A short description of 
each species is given prior to each species balance expression. Note that, as before, species are 
defined based on their type and location in order to recognize the spatial differences in the 
trafficking pathway. To clarify, any species referred to as “reduced” (e.g., reduced FeTfDT/TfR 
complex and reduced TfDT/DTR complex) signifies that the disulfide bond between the DTA and 
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DTB domains of DT has been cleaved through the process defined by the rate constant ktrans. 
Therefore, reduced versions of the Tf-DT conjugates (i.e., FeTfDT and TfDT) are represented in 
the species balances as FeTfDTB and TfDTB. The rate constant, ktrans, also captures the process 
by which DTA translocates into the cytosol following this disulfide reduction. 
 
 
Table 2.3 List of species and parameters in the Tf-DT trafficking model. 
 
 
 
Species Definition  Species Definition 
FeTfDTbulk Bulk extracellular iron-bound 
Tf-DT (FeTfDT) 
 TfDT_TfRtub Tubular TfDT/TfR complex 
TfDTbulk Bulk extracellular iron-free Tf-
DT (TfDT) 
 FeTfDTdeg Degraded FeTfDT 
TfRsurf Surface TfR  TfDTdeg Degraded TfDT 
DTRsurf Surface DTR  TfRdeg Degraded TfR 
FeTfDT_TfRsurf Surface FeTfDT/TfR complex  DTRdeg Degraded DTR 
TfDT_TfRsurf Surface TfDT/TfR complex  FeTfDT_TfRdeg Degraded FeTfDT/TfR 
complex 
FeTfDT_DTRsurf Surface FeTfDT/DTR complex  TfDT_TfRdeg Degraded TfDT/TfR complex 
TfDT_DTRsurf Surface TfDT/DTR complex  FeTfDTB_TfRdeg Degraded reduced 
FeTfDT/TfR complex 
FeTfDTves Vesicular FeTfDT  TfDTB_TfRdeg Degraded reduced TfDT/TfR 
complex 
TfDTves Vesicular DT  FeTfDT_DTRdeg Degraded FeTfDT/DTR 
complex 
TfRves Vesicular TfR  TfDT_DTRdeg Degraded TfDT/DTR complex 
DTRves Vesicular DTR  FeTfDTB_DTRdeg Degraded reduced 
FeTfDT/DTR complex 
FeTfDT_TfRves Vesicular FeTfDT/TfR 
complex 
 TfDTB_DTRdeg Degraded reduced TfDT/DTR 
complex 
TfDT_TfRves Vesicular TfDT/TfR complex  FeTfDTrec Recycled FeTfDT 
FeTfDTB_TfRves Vesicular reduced 
FeTfDT/TfR complex 
 TfDTrec Recycled TfDT 
TfDTB_TfRves Vesicular reduced TfDT/TfR 
complex 
 TfRrec Recycled TfR 
FeTfDT_DTRves Vesicular FeTfDT/DTR 
complex 
 FeTfDT_TfRrec Recycled FeTfDT/TfR 
complex 
TfDT_DTRves Vesicular TfDT/DTR complex  TfDT_TfRrec Recycled TfDT/TfR complex 
FeTfDTB_DTRves Vesicular reduced 
FeTfDT/DTR complex 
 DTAcyt Cytosolic DTA 
TfDTB_DTRves Vesicular reduced TfDT/DTR 
complex 
 k Vesicular/tubule partition 
coefficient 
TfRtub Tubular TfR  h Tubule to vesicle volume ratio 
FeTfDT_TfRtub Tubular FeTfDT/TfR complex  g TfR-mediated vesicle to tubule 
rate constant 
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Bulk and Surface Equations 
Species balance for bulk extracellular iron-bound Tf-DT (FeTfDT) 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝑑𝑡 = −𝑘b8.2𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 + 𝑘b8.2,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘-.𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12+ 𝑘-.,1𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 + 𝑘187𝐹𝑒𝑇𝑓𝐷𝑇187 𝑛78&&𝑉$%&'𝑁; 
Species balance for bulk extracellular iron-free Tf-DT (TfDT) 𝑑 𝑇𝑓𝐷𝑇$%&'𝑑𝑡 = −𝑘.2𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 + 𝑘.2,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘-.𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12+ 𝑘-.,1𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 + 𝑘187𝑇𝑓𝐷𝑇187 𝑛78&&𝑉$%&'𝑁; 
Species balance for surface TfR 𝑑 𝑇𝑓𝑅0%12𝑑𝑡 = −𝑘b8.2𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 + 𝑘b8.2,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 	− 𝑘.2𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 + 𝑘.2,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘<=>,.2𝑇𝑓𝑅0%12+ 𝑘187𝑇𝑓𝑅187 + 𝑘?8@,.2𝑇𝑓𝑅?8@ + 𝑘?8@,.2𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@+ 𝑘?8@,.2𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@ + 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@+ 𝑘?8@,-.𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@		 
Species balance for surface DTR 𝑑 𝐷𝑇𝑅0%12𝑑𝑡 = −𝑘-.𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12 + 𝑘-.,1𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 − 𝑘-.𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12+ 𝑘-.,1𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 − 𝑘<=>,-.𝐷𝑇𝑅0%12 + 𝑘?8@,-.𝐷𝑇𝑅?8@+ 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@ + 𝑘?8@,-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@+ 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@ + 	𝑘?8@,-.𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@			 
Species balance for surface FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12𝑑𝑡 = 𝑘b8.2𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 − 𝑘b8.2,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘<=>,.2𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12+ 𝑘187𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187 
(2.19) 
(2.20) 
(2.23) 
(2.21) 
(2.22) 
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Species balance for surface TfDT/TfR complex 𝑑 𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12𝑑𝑡 = 𝑘.2𝑇𝑓𝐷𝑇$%&'𝑇𝑓𝑅0%12 − 𝑘.2,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘<=>,.2𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12+ 𝑘187𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187 
 
Species balance for surface FeTfDT/DTR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12	𝑑𝑡 = 𝑘-.𝐹𝑒𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12 − 𝑘-.,1𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12	– 𝑘<=>,-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12	 
 
Species balance for surface TfDT/DTR complex 𝑑 𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12𝑑𝑡 = 𝑘-.𝑇𝑓𝐷𝑇$%&'𝐷𝑇𝑅0%12 − 𝑘-.,1𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 	− 𝑘<=>,-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 
 
Vesicular Equations 
Species balance for vesicular FeTfDT 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇d80𝑑𝑡 = −𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇d80 − 𝑘8=?e𝐹𝑒𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e + 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80
− 𝑘8=?e𝐹𝑒𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅>%$𝑁;𝑉8=?e + 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$k − 𝑘0d𝐹𝑒𝑇𝑓𝐷𝑇d801 + 𝜂
− 𝜂𝑘0>𝐹𝑒𝑇𝑓𝐷𝑇d80	1 + 𝜂  
Species balance for vesicular TfDT 𝑑 𝑇𝑓𝐷𝑇d80𝑑𝑡 = 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇d80 − 𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e + 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80
− 𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅>%$𝑁;𝑉8=?e + 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$𝜅 − 𝑘0d𝑇𝑓𝐷𝑇d801 + 𝜂 − 𝜂𝑘0>𝑇𝑓𝐷𝑇d801 + 𝜂  
 
 
(2.24) 
(2.25) 
(2.26) 
(2.27) 
(2.28) 
	 24 
Species balance for vesicular TfR 𝑑 𝑇𝑓𝑅d80𝑑𝑡 = 𝑘<=>,.2𝑇𝑓𝑅0%12 − 𝑘8=?e𝐹𝑒𝑇𝑓	𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e + 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80
− 𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e + 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝛾𝑇𝑓𝑅d80 − 𝑘0d𝑇𝑓𝑅d80 
 
Species balance for vesicular DTR 𝑑(𝐷𝑇𝑅d80)𝑑𝑡 = 𝑘<=>,-.𝐷𝑇𝑅0%12 − 𝑘&A0𝐷𝑇𝑅d80 
Species balance for vesicular FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80𝑑𝑡
= 𝑘<=>,.2𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 − 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 + 𝑘8=?e𝐹𝑒𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e− 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘>1D=0𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝛾𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80− 𝑘0d𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 
 
Species balance for vesicular TfDT/TfR complex 𝑑(𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80)𝑑𝑡
= 𝑘<=>,.2𝑇𝑓𝐷𝑇_𝑇𝑓𝑅0%12 + 𝑘b8,18&	𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 + 𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅d80𝑁;𝑉8=?e− 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘>1D=0𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝛾𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘0d𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 
 
Species balance for vesicular reduced FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80𝑑𝑡 = 𝑘>1D=0𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 − 𝑘&A0𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 
 
 
(2.29) 
(2.30) 
(2.33) 
(2.31) 
(2.32) 
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Species balance for vesicular reduced TfDT/TfR complex 𝑑 𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80𝑑𝑡 = 𝑘>1D=0𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 + 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 − 𝑘&A0𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 
 
Species balance for vesicular FeTfDT/DTR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80𝑑𝑡 = 𝑘<=>,-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 − 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘>1D=0𝑓-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80− 𝑘&A0 1 − 𝑓-. 𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 
 
Species balance for vesicular TfDT/DTR complex 𝑑 𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80𝑑𝑡 = 𝑘<=>,-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅0%12 + 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘>1D=0𝑓-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80− 𝑘&A0 1 − 𝑓-. 𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 
 
Species balance for vesicular reduced FeTfDT/DTR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80𝑑𝑡 = 𝑘>1D=0𝑓-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 − 𝑘&A0𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 
 
Species balance for vesicular reduced TfDT/DTR complex 𝑑 𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80𝑑𝑡 = 𝑘>1D=0𝑓-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 + 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 − 𝑘&A0𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 
 
 
 
 
(2.34) 
(2.35) 
(2.36) 
(2.37) 
(2.38) 
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Tubular Equations 
Species balance for tubular TfR 𝑑 𝑇𝑓𝑅>%$𝑑𝑡 = −𝜅𝑘8=?e𝐹𝑒𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅>%$𝑁;𝑉8=?e + 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ − 𝜅𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅>%$𝑁;𝑉8=?e+ 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ + 𝛾𝑇𝑓𝑅d80 
 
Species balance for tubular FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$𝑑𝑡
= −𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ + 𝜅𝑘8=?e𝐹𝑒𝑇𝑓𝐷𝑇d80𝑁;𝑉8=?e − 𝑘8=?e,1𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$+ 𝛾𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘0>𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ 
Species balance for tubular TfDT/TfR complex 𝑑(𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$)𝑑𝑡
= 𝑘b8,18&𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ + 𝜅𝑘8=?e𝑇𝑓𝐷𝑇d80𝑇𝑓𝑅>%$𝑁;𝑉8=?e − 𝑘8=?e,1𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$+ 	𝛾𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘0>𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ 
 
Degradation Equations 
Species balance for degraded FeTfDT 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇?8@𝑑𝑡 = 𝑘0d𝐹𝑒𝑇𝑓𝐷𝑇d801 + 	𝜂 − 𝑘?8@,.2𝐹𝑒𝑇𝑓𝐷𝑇?8@ 
Species balance for degraded TfDT 𝑑 𝑇𝑓𝐷𝑇?8@𝑑𝑡 = 𝑘0d𝑇𝑓𝐷𝑇d801 + 𝜂 − 𝑘?8@,.2𝑇𝑓𝐷𝑇?8@	 
Species balance for degraded TfR 𝑑 𝑇𝑓𝑅?8@𝑑𝑡 = 𝑘0d𝑇𝑓𝑅d80 − 𝑘?8@,.2𝑇𝑓𝑅?8@	 
(2.41) 
(2.42) 
(2.43) 
(2.44) 
(2.39) 
(2.40) 
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Species balance for degraded DTR 𝑑 𝐷𝑇𝑅?8@𝑑𝑡 = 𝑘&A0𝐷𝑇𝑅d80 − 𝑘?8@,-.𝐷𝑇𝑅?8@	 
Species balance for degraded FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@𝑑𝑡 = 𝑘0d𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘?8@,.2𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@ 
Species balance for degraded TfDT/TfR complex 𝑑 𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@𝑑𝑡 = 𝑘0d𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 − 𝑘?8@,.2𝑇𝑓𝐷𝑇_𝑇𝑓𝑅?8@		 
Species balance for degraded reduced FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@𝑑𝑡 = 𝑘&A0𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 − 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@	 
Species balance for degraded reduced TfDT/TfR complex 𝑑 𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@𝑑𝑡 = 𝑘&A0𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅d80 − 𝑘?8@,-.𝑇𝑓𝐷𝑇𝐵_𝑇𝑓𝑅?8@ 
Species balance for degraded FeTfDT/DTR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@𝑑𝑡 = 𝑘&A0 1 − 𝑓-. 𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@	 
 
Species balance for degraded TfDT/DTR complex 𝑑 𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@𝑑𝑡 = 𝑘&A0 1 − 𝑓-. 𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 − 𝑘?8@,-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅?8@ 
 
Species balance for degraded reduced FeTfDT/DTR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@𝑑𝑡 = 𝑘&A0𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 − 𝑘?8@,-.𝐹𝑒𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@ 
 
Species balance for degraded reduced TfDT/DTR complex 𝑑 𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@𝑑𝑡 = 𝑘&A0𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅d80 − 𝑘?8@,-.𝑇𝑓𝐷𝑇𝐵_𝐷𝑇𝑅?8@	 
(2.45) 
(2.48) 
(2.49) 
(2.50) 
(2.51) 
(2.52) 
(2.53) 
(2.46) 
(2.47) 
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Recycling Equations 
Species balance for recycled FeTfDT 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇187𝑑𝑡 = 𝜂𝜅𝑘0>𝐹𝑒𝑇𝑓𝐷𝑇d801 + 𝜂 − 𝑘187𝐹𝑒𝑇𝑓𝐷𝑇187 
Species balance for recycled TfDT 𝑑 𝑇𝑓𝐷𝑇187𝑑𝑡 = 𝜂𝜅𝑘0>𝑇𝑓𝐷𝑇d801 + 𝜂 − 𝑘187𝑇𝑓𝐷𝑇187 
Species balance for recycled TfR 𝑑 𝑇𝑓𝑅187𝑑𝑡 = 𝑘0>𝑇𝑓𝑅>%$ − 𝑘187𝑇𝑓𝑅187	 
Species balance for recycled FeTfDT/TfR complex 𝑑 𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187𝑑𝑡 = 𝑘0>𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ − 𝑘187𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187 
Species balance for recycled TfDT/TfR complex 𝑑 𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187𝑑𝑡 = 𝑘0>𝑇𝑓𝐷𝑇_𝑇𝑓𝑅>%$ − 𝑘187𝑇𝑓𝐷𝑇_𝑇𝑓𝑅187 
 
Cytosolic Equations 
Species balance for cytosolic DTA 
𝑑 𝐷𝑇𝐴7A>𝑑𝑡 = 𝑘>1D=0𝐹𝑒𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 + 𝑘>1D=0𝑇𝑓𝐷𝑇_𝑇𝑓𝑅d80 + 𝑘>1D=0𝑓-.𝐹𝑒𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 + 𝑘>1D=0𝑓-.𝑇𝑓𝐷𝑇_𝐷𝑇𝑅d80 
 
Model Parameters 
Mutant Tf conjugates were differentiated from wild-type Tf conjugates by altering the iron 
release rate within cellular endosomes, kFe,rel, such that mutant Tf conjugates had a lower kFe,rel. 
CRM107 conjugates were differentiated from DT conjugates by altering the binding affinity to 
DTR. CRM107’s decreased binding affinity for DTR was modeled by setting the DT to DTR 
(2.54) 
(2.55) 
(2.56) 
(2.57) 
(2.58) 
(2.59) 
	 29 
association rate constant, kDT, of Tf-CRM107 simulations to be 8,000-fold less than its value for 
Tf-DT simulations. Note that this same distinction between Tf-DT and Tf-CRM107 conjugates 
can also be accomplished by increasing the DT to DTR dissociation rate constant, kDT,r, by 8,000-
fold for Tf-CRM107 simulations since KD = kDT r/kDT. It was found with the cellular toxicity 
simulations that either method produced the same outcome. The results in Section 3 correspond to 
decreasing the association rate constant for Tf-CRM107 conjugates. In addition, the same rate 
constant for TfR-mediated internalization was assumed for both Tf and its mutant. This was 
deduced from the fact that the TfR-mediated internalization rate constant remains the same 
regardless of whether there is Tf bound to TfR, which suggests that the internalization rate constant 
would not depend on the type of Tf bound to TfR [68]. A full list of model parameters is provided 
in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
	 30 
Rate 
Constant 
Definition Value Ref. 
kFeTf Association rate constant of 
FeTfDT for TfR 
(9.6 ± 0.2) ´ 107 M-1 min-1 (Lebron et al., 1998) 
kFeTf,r Dissociation rate constant of 
FeTfDT for TfR 
(7.8 ± 1.2) ´ 10-2 min-1 (Lebron et al., 1998) 
kTf Association rate constant of 
TfDT for TfR 
0 M-1 min-1 (Lebron et al., 1998) 
kTf,r Dissociation rate constant of 
TfDT for TfR 
2.6 min-1 (Ciechanover et al., 1983) 
kDT Association rate constant of 
(Fe)TfDT for DTR 
1.90 ´ 107 M-1 min-1 a 
2.375 ´ 103 M-1 min-1 b 
Est. 
kDT,r Dissociation rate constant of 
(Fe)TfDT for DTR 
1.90 ´ 10-2 min-1 Est. 
kendo Endosomal association rate 
constant of (Fe)TfDT for TfR 
(4.4 ± 0.4) ´ 107 M-1 min-1 (Lebron et al., 1998) 
kendo,r Endosomal dissociation rate 
constant of (Fe)TfDT for TfR 
(5.6 ± 1.2) ´ 10-2 min-1 (Lebron et al., 1998) 
kint,Tf TfR-mediated internalization 
rate constant 
2.0 ´ 10-1 min-1 (Ciechanover et al., 1983) 
kint,DT DTR-mediated internalization 
rate constant 
2.8 ´ 10-2 min-1 (Dorland et al., 1979) 
kFe,rel Endosomal Tf iron release rate 
constant 
1.0 ´ 102 min-1 c 
1.0 ´ 10-3 min-1 d 
Est. 
ktrans Vesicle to cytosol translocation 
rate constant 
1.5 ´ 10-1 min-1 Est. 
ksv TfR-mediated degradation rate 
constant 
1.2 ´ 10-1 min-1 (French and Lauffenburger, 1997) 
kst TfR-mediated tubule to 
recycling rate constant 
5.3 ´ 10-1 min-1 (French and Lauffenburger, 1997) 
kdeg,Tf TfR-mediated degradation rate 
constant 
6.0 ´ 10-2 min-1 (French and Lauffenburger, 1997) 
krec TfR-mediated recycling rate 
constant 
1.5 ´ 10-1 min-1 (French and Lauffenburger, 1997) 
k Vesicle/tubule partition 
coefficient 
0.44 Est. 
h Tubule to vesicle volume ratio 0.43 (French and Lauffenburger, 1997) 
g TfR-mediated vesicle to tubule 
rate constant 
1.0 min-1 (French and Lauffenburger, 1997) 
klys DTR-mediated vesicle to 
lysosome transfer rate constant 
1.8 ´ 10-1 min-1 Est. 
kdeg,DT DTR-mediated degradation rate 
constant 
4.0 ´ 10-2 min-1 Est. 
fDT Endosome to cytosol 
translocation fraction 
0.33 (Dorland et al, 1979) 
ncell Cell number 4 ´ 105 cells N/A 
Vbulk Bulk media volume 1 ´ 10-3 L N/A 
Vendo Endosomal volume 1.0 ´ 10-14 L (French and Lauffenburger, 1997) 
NA Avogadro’s number 6.02 ´ 1023 mol-1 N/A 
 
aWild-type DT 
bCRM107 
cWild-type Tf  
dMutant Tf 
Table 2.2 List of parameters in the Tf-DT conjugate intracellular trafficking model. 
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2.2.3 Synthesis and Purification 
Synthesis and Purification of CRM107 
CRM107 was first developed by Laird and Groman and purified as described previously 
by Youle and coworkers [39], [69]. Briefly, Corynebacterium diphtheria cultures were clarified 
by centrifugation, incubated in 65% ammonium sulfate at 4°C overnight, and subsequently 
centrifuged and resuspended in 50 mM tris(hydroxymethyl)aminomethane (Tris) buffer with 0.1 
mM ethylenediaminetetraacetic acid (EDTA) at pH 8.0. The solution was then dialyzed overnight 
at 4°C in the same buffer with 0.1 mM phenylmethylsulfonyl fluoride added. CRM107 was 
isolated by ion-exchange chromatography using a DEAE-Sepharose Fast Flow column (GE 
Healthcare Life Sciences, Marlborough, MA).  
 
Synthesis and Purification of Tf Mutants 
The generation of Tf mutants with site-directed mutagenesis was previously described. 
[61], [70], [71]. The mutant Tf expression vectors were pNUT N-His K206E/K534A hTf NG and 
pNUT NHis K206E/R632A hTf NG, which coded for two Tf mutants with changes to both iron 
binding lobes. Furthermore, pNUT N-His hTf NG expression vector (native Tf) was also created 
to serve as the control for the two Tf mutants. The production and purification of the recombinant 
Tf was previously described [70], [71]. Briefly, baby hamster kidney cells were used for the 
expression of secreted recombinant Tf, and the protein was subsequently purified from the cell 
culture medium. 
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2.2.4 Cell Culture 
U251 human glioma cells were a kind gift from Drs. Robert M. Prins and Linda M. Liau 
(UCLA Neurosurgery). Normal human astrocytes (NHAs) were purchased from Lonza (Rockland, 
ME). U87 human glioma cells, human umbilical vein endothelial cells (HUVECs), and HeLa cells 
were purchased from American Type Culture Collection (ATCC). All cells were seeded on 75 cm2 
culture flasks (Corning, Corning, NY) for everyday passaging. U251, U87, and HeLa cells were 
grown in Dulbecco’s Modified Eagle Medium supplemented with high glucose (DMEM-HG; 
Invitrogen, Carlsbad, CA) with 3.6 g/L sodium bicarbonate, 10% fetal bovine serum (FBS; 
Hyclone, Logan, UT), 1 mM sodium pyruvate, 100 units/mL penicillin (Invitrogen), and 100 
µg/mL streptomycin (Invitrogen) at a pH of 7.4. HUVECs were grown in Ham’s F12 Medium 
with Kaighn’s Modification (F12K) with 2.5 g/L sodium bicarbonate, 10% FBS, 0.1 mg/mL 
porcine heparin, 0.03 mg/mL endothelial cell growth supplement, 1 mM sodium pyruvate, 100 
units/mL penicillin (Invitrogen), and 100 µg/mL streptomycin (Invitrogen) at a pH of 7.4. NHAs 
were grown in Astrocyte Growth Medium (AGM; Lonza). All cell culture media described above 
will be referred to as growth media. The cells were incubated in a humidified atmosphere with 5% 
CO2 at 37°C. All reagents and materials were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise specified. 
 
2.2.5 Conjugation of Recombinant Tf to CRM107 
CRM107 conjugates of recombinant Tf were prepared using the chemical crosslinkers 2-
iminothiolane (IT; Pierce, Rockford, IL) and N-succinimidyl 3-(2-pyridyldithio)propionate 
(SPDP; Pierce) to create a reducible disulfide bond. CRM107 in borate buffer (100 mM sodium 
borate, 3.5 mM EDTA, pH 8.0) was thiolated with a 2.0-fold molar excess of 2-IT for 60 min at 
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room temperature. The thiolated CRM107 was separated from free 2-IT using Zeba desalting spin 
columns (Pierce). Recombinant Tf in phosphate-buffered saline (PBS; 50 mM sodium phosphate, 
0.15 M NaCl, pH 7.4) was reacted with a 3.0-fold molar excess of SPDP for 30 min at room 
temperature. This SPDP modified Tf (Tf-SPDP) was separated from free SPDP using Zeba 
desalting spin columns. The Tf-SPDP and the thiolated CRM107 (1:1 molar ratio) were mixed, 
diluted, and incubated for 20 h at 4°C. The Tf-CRM107 conjugate was then purified by HPLC 
(AKTA FPLC Chromatographic System, GE Healthcare Bio-Sciences, Piscataway, NJ) using two 
HiPrep 16/60 Sephacryl S200HR size-exclusion columns in series (GE Healthcare Bio-Sciences). 
The identity of each peak was confirmed by SDS-PAGE and the concentration quantified using 
the Bradford dye binding assay (Bradford, 1976). The Tf-CRM107 conjugate was stored in PBS 
containing 20 mM sodium bicarbonate. 
 
2.2.6 In Silico Cytotoxicity 
Cellular Toxicity in Cancerous Cells  
Model equations were solved with Berkeley Madonna™ using initial conditions set to zero 
for all species except the concentration of holo-Tf-DT (1 nM), the number of TfR on the cell 
surface (5.4 × 105 receptors [43]), and the number of DTR on the cell surface (1.5 × 105 receptors 
[54]). The length of each simulation was 50 h. Wild-type Tf conjugates were distinguished from 
mutant Tf conjugates by setting the endosomal iron release rate constant, kFe,rel, to 100 min-1 and 
0.001 min-1, respectively. Tf-CRM107 conjugate trafficking was distinguished from Tf-DT 
conjugate trafficking by reducing the association rate constant for toxin binding to DTR (kDT) to 
be 8,000-fold less.  
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Cellular toxicity was investigated by examining the % inhibition of cellular growth at 
various concentrations of the Tf-toxin conjugate. Tf-toxin conjugate-induced cellular toxicity was 
estimated using the following approach. First, based on our previous Tf-DT conjugate in vitro 
toxicity studies with U251 and U87 cells, maximum wild-type Tf-DT toxicity initially plateaued 
at a conjugate concentration of 3.16 × 10-11 M for both cell lines [46]. The number of molecules 
of DT’s catalytic domain (DTA) found in the cytosol at this concentration was determined from 
trafficking simulations to be 1.51 × 104 molecules/cell, and this was fixed as the number of DTA 
molecules necessary to exhibit 100% cellular toxicity for our model simulations. Lower 
concentrations of conjugates were also input into the trafficking model to generate a cytotoxicity 
curve. After determining the number of DTA molecules in the cytosol, the value was divided by 
1.51 × 104 and multiplied by 100% to yield the corresponding % inhibition value.  
 
Cellular Toxicity in Non-Neoplastic Cells  
Cellular toxicity for non-neoplastic cells was investigated similarly to the procedure 
outlined in Section 2.3.1, with the exception of the initial value of surface Tf receptors. Since 
cancerous cells are known to overexpress surface TfR, non-neoplastic cells were modeled by 
decreasing the initial surface TfR of cancerous cells, 5.4 × 105 receptors, by various fold [2], [43]. 
Since non-neoplastic cells were expected to have at least 10-fold fewer TfR than cancerous cells, 
this investigation was started at a 10-fold decrease of TfR.  
 
2.2.7 In Vitro Cytotoxicity  
Tf-toxin conjugates were synthesized and various cell lines were cultured according to 
methods detailed previously. The sulforhodamine B (SRB) cell proliferation assay was used to 
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quantify cell survival based on the measurement of cellular protein content. The toxicities of the 
mutant Tf-CRM107 conjugates relative to the wild-type Tf-CRM107 conjugate were investigated 
in glioma cells (U87 and U251) and HeLa cells to determine if the mutant Tf conjugates were more 
potent than the wild-type Tf conjugate using the new toxin. In addition, mutant Tf-CRM107 
conjugates were incubated with normal cells to assess cancer specificity.  
The various cells utilized in this study were seeded onto wells of a 96-well tissue culture 
plate at cell densities of 10,000 cells/cm2 for cancer cells (U87, U251, and HeLa) and 45,000 
cells/cm2 for normal cells (human umbilical vein endothelial cell (HUVEC) and normal human 
astrocyte (NHA)). Different seeding densities were used due to differences in cell size and 
proliferation rate.  Following overnight incubation, growth medium was aspirated, and the cells 
were incubated for 48 h with 100 µL fresh growth medium containing concentrations of Tf-
CRM107 spanning five orders of magnitude (10-13 to 10-9 M).  A cold 10% trichloroacetic acid 
(TCA) solution (100 µL) was added to each well to fix the cells at 4°C for 1 h. The 10% TCA 
solution was removed, and the cells were washed four times with deionized water then thoroughly 
blow-dried. Subsequently, 50 µL of a 1% acetic acid solution containing 0.4% SRB was added to 
each well for 30 min at room temperature. The dye solution was removed, and the cells were 
washed four times with a 1% acetic acid solution to remove unbound dye; following this step, the 
cells were again blow-dried. The dye was dissociated from the proteins and solubilized with 100 
µL of a 10 mM Tris base solution. The absorbance of each well was determined with an Infinite 
F200 plate reader (Tecan System Inc., San Jose, CA) at wavelengths of 560 and 700 nm. The 
survival of cells relative to a control (i.e., cells incubated in growth medium without Tf-CRM107) 
was calculated by determining the ratio of the (A560 - A700) values. Experiments were performed 
three times with quadruplicate points per concentration. 
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2.3 Results and Discussion 
2.3.1 Sensitivity Analysis of the Parameters Associated with the DT/DTR Intracellular 
Trafficking Pathway  
 All parameters associated with the DTR-mediated internalization pathway were examined 
to investigate the effects of this alternative internalization pathway on the overall cellular toxicity 
between wild-type and mutant Tf-DT conjugates. Tf-CRM107 conjugates were largely ignored in 
these analyses since the effect of varying these DT related parameters on a conjugate with an 
8,000-fold decreased binding affinity for DTR produced negligible changes, as illustrated for two 
such parameters in Fig 2.3.  
 
Fig 2.3 Predicted response in cellular toxicity to changes in the (A) degradation and (B) lysosomal sorting rate 
constants of Tf-CRM107 conjugates internalized through the DT receptor. 
 
The effect of cell surface DTR expression on the cellular toxicity of wild-type and mutant 
Tf-DT conjugates were examined (Fig 2.4A). As the expression of cell surface DTR increased, the 
cellular toxicity of wild-type Tf-DT conjugates drastically increased, as indicated by decreasing 
IC50 values, with a maximum toxicity observed at an expression level of 106 receptors/cell. Beyond 
this point, the cytotoxic efficacy of wild-type Tf-DT conjugates slightly decreased. This suggests 
a balance between an increase in cytotoxic efficacy due to the increasing availability of DTR-
mediated endocytic entry sites and a decrease in efficacy due to the increasing lysosomal 
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degradation of wild-type Tf-DT conjugates through DTR-mediated endocytosis. Similarly, this 
decrease is also observed for mutant Tf-DT conjugates at an expression level beyond 106 
receptors/cell. However, the initial increase in the number of cell surface DTR has a negligible 
effect on the cytotoxic efficacy of mutant Tf-DT conjugates. This observation supports the 
hypothesis that the improved cellular association of mutant Tf is sufficient for optimal delivery of 
toxin, whether it be DT or CRM107. The same trend in toxicity is observed for the sensitivity 
analysis of kDT and kDT,r (Figs 2.4B and C) since altering the binding affinity of DT for its receptor 
has the similar effect as altering cell surface DTR expression. 
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Fig 2.4 Predicted response in cellular toxicity to changes in DT parameters. Dashed lines indicate native DT values 
for each property. Note change in y-axis scale for (G). 
 
 The one difference with the analysis of kDT,r is that there is no observable local minimum 
for the Tf-DT conjugate IC50 curve (Fig 2.4C). This is unique to the dissociation rate constant 
since the dissociation of DT from DTR is not possible until the conjugate binds to its receptor. At 
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this junction, the conjugate can either dissociate from its receptor, or become internalized. The 
lack of an IC50 minimum is attributed to the fact that as you decrease kDT,r to a value lower than 
the native internalization rate constant of DT, kint,DT (0.028 min-1), the internalization process 
dominates, leading to no further changes in IC50. 
 Analyses of kint,DT  and klys (Figs 2.4D and E) demonstrated similar profiles as those 
observed for the analyses of cell surface DTR expression and kDT. Initially, increasing both rate 
constants increased the cytotoxic efficacy of wild-type Tf-DT conjugates, but the efficacy of wild-
type Tf-DT conjugates began to decrease beyond values of 10-2 min-1. This behavior, with respect 
to kint,DT, occurs since increasing the rate of wild-type Tf-DT conjugate internalization will initially 
enhance delivery of DT to the cytosol and improve cytotoxicity. However, since DTR can become 
internalized without first binding to the conjugate, higher internalization rates can lead to a rapid 
decrease in cell surface DTR expression with localization in the endosome, resulting in the 
observed decrease in cytotoxic efficacy. In terms of klys, while the initial increase also facilitates 
the DTR-mediated delivery of the wild-type Tf-DT conjugate, higher lysosomal sorting rates limit 
the residence time of these conjugates within the endosome. Since the translocation of DTA occurs 
at the pre-lysosomal endosome, this shorter endosomal residence time negatively impacts the 
conjugate’s cytotoxic efficacy. 
 Increasing the degradation rate constant, kdeg,DT , exhibits an increase in wild-type Tf-DT 
conjugate cytotoxic efficacy (Fig 2.4F), which plateaus at a value of 10-1 min-1. This observation 
is not surprising due to the model assumption that the total number of DTR remains at steady-state. 
For this reason, as the degradation rate of proteins in the DTR-mediated intracellular trafficking 
pathway increases, more free receptors are returned to the cell surface, allowing more wild-type 
Tf-DT conjugates to enter the cell. 
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 Increasing the endosome to cytosol translocation fraction, fDT, and the endosome to cytosol 
translocation rate constant, ktrans, leads to an increase in cytotoxic efficacy for wild-type Tf-DT 
conjugates, as expected (Figs 2.4G and H). This is because an increase in both of these parameters 
leads to an increased delivery of DTA to the cytosol, improving its cytotoxic efficacy.   
 Finally, it is important to note that the cytotoxic efficacy of mutant Tf-DT conjugates is 
only negligibly affected by changes to all DT parameters, with the exception of ktrans. This is likely 
due to the fact that the improved cellular association of mutant Tf is sufficient for optimal delivery 
of toxin despite alterations to the DTR-mediated trafficking pathway, as discussed previously. The 
exception found with ktrans is ascribed to its contribution to DTA translocation in both DTR- and 
TfR-mediated intracellular trafficking pathways. 
 
2.3.1 Tf-DT Mathematical Model Successfully Predicts Improved Efficacy of Mutant Tf-
CRM107 Conjugates against Cancer Cells Relative to Wild-Type Tf-CRM107 Conjugates 
Simulations with our Tf-DT conjugate intracellular trafficking model were performed to 
determine differences in cytotoxicity between wild-type and mutant Tf proteins with both DT and 
CRM107 conjugates. The predicted trends were then validated with in vitro cytotoxicity data.  
Fig 2.5 and Table 2.3 presents the results of our in silico toxicity simulations. The 
concentrations at which 50% inhibition of cellular growth (IC50) was observed were 13.4, 8.66, 
36.8, and 8.20 pM for wild-type Tf-DT, mutant Tf-DT, wild-type Tf-CRM107, and mutant Tf-
CRM107, respectively (Table 2.3). These results indicate that mutant Tf conjugates have increased 
drug efficacy compared to the wild-type conjugates. In addition, the difference in drug delivery 
efficacy between wild-type and mutant Tf was only 1.5-fold for DT conjugates, while the 
difference for CRM107 conjugates was 4.5-fold. This suggests that changing the toxin moiety of 
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our Tf-based cancer therapeutic from DT to CRM107 can potentially increase the difference in 
drug efficacy.  
 
Fig 2.5 Cytotoxicity simulation of wild-type Tf versus mutant Tf conjugates. In silico cytotoxicity simulations using 
the Tf-DT mathematical model for (A) wild-type and mutant Tf-DT conjugates and (B) wild-type and mutant Tf-
CRM107 conjugates.  
 
Conjugate IC50 (pM) IC50 decrease 
associated with 
mutant Tf 
DT conjugates   
Wild-type Tf-DT 13.4  
1.5-fold Mutant Tf-DT 8.66 
CRM107 conjugates   
Wild-type Tf-
CRM107 
36.8  
4.5-fold 
Mutant Tf-CRM107 8.20 
 
Table 2.3 Simulation IC50 values of DT conjugates versus CRM107 conjugates. Mutant Tf conjugates exhibit 
improved efficacy compared to their wild-type Tf counterparts. Changing the toxin moiety to CRM107 results in an 
improved fold difference between the mutant Tf and the wild-type Tf conjugates.   
 
The difference in cytotoxicity between CRM107 and DT was as predicted because the 
wild-type Tf-CRM107 conjugate was estimated to be associated to a lesser degree with the cell 
than the wild-type Tf-DT conjugate, since CRM107 cannot bind to DTR (the preHB-EGF 
receptor). Wild-type Tf is often assumed to be restricted to a single cycle through its trafficking 
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pathway due to its highly efficient iron delivery kinetics [43], [60]. For this reason, wild-type Tf-
CRM107 conjugates would typically have a single opportunity to deliver their cytotoxic payload, 
which is insufficient for the effective delivery of CRM107 given the short intracellular residence 
time of a single Tf/TfR trafficking cycle [72]. On the other hand, wild-type Tf-DT conjugates are 
given an additional opportunity to deliver their cytotoxic payload even after the loss of iron 
because of DT’s high affinity for its own receptor. Coupled with the greater intracellular residence 
time associated with the DT/DTR degradation pathway, it is not surprising that the cytotoxicity of 
wild-type Tf-DT conjugates is significantly greater than the cytotoxicity of wild-type Tf-CRM107 
conjugates [53].  
To confirm these trends predicted by the Tf-DT conjugate intracellular trafficking and 
toxicity model, we synthesized and administered CRM107 conjugates of our wild-type, 
K206E/R632A, and K206E/K534A Tf ligands to two glioma (U251 and U87) cell lines as well as 
the HeLa cell line over a range of concentrations for 48 h. In accordance with our model, each 
mutant Tf-CRM107 conjugate exhibited a significantly enhanced drug delivery efficacy relative 
to their wild-type counterpart in U87, U251, and HeLa cells that was much greater than the 
improved efficacy observed with Tf-DT conjugates (Fig 2.6, Table 2.4). IC50 values for U87 cells 
(Figs 2.6A and B, Table 2.4) were determined to be 32.1 ± 3.2 pM for wild-type Tf compared to 
values of 7.10 ± 0.87 (p = 0.0002) and 6.80 ± 0.52 pM (p = 0.0002) for K206E/R632A Tf and 
K206E/K534A Tf, respectively. Similar results were obtained with U251 cells (Figs 2.6C and D, 
Table 2.4), demonstrating IC50 values of 35.3 ± 3.7 pM for wild-type Tf compared to values of 
10.8 ± 1.8 (p = 0.0005) and 11.3 ± 1.2 pM (p = 0.0004) for K206E/R632A Tf and K206E/K534A 
Tf, respectively. For HeLa cells (Figs 2.6E and F, Table 2.4), the IC50 values were determined to 
be 30.3 ± 3.0 pM for wild-type Tf compared to values of 9.4 ± 1.0 (p = 0.0002) and 10.2 ± 1.4 pM 
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(p = 0.0003) for K206E/R632A Tf and K206E/K534A Tf, respectively. The student’s t-test was 
used to show that the decrease in IC50 exhibited by both mutant Tf-CRM107 conjugates compared 
to the wild-type counterpart was statistically significant (p < 0.05). These experiments showed that 
mutant Tf-CRM107 conjugates exhibited an improved efficacy compared to wild-type Tf-
CRM107 conjugates (4.6, 3.2, and 3.0 fold for U87, U251, and HeLa cells). The fold improvement 
observed with the mutant Tf-CRM107 conjugates relative to the wild-type Tf-CRM107 conjugate 
was greater than the fold improvement observed with the mutant Tf-DT conjugates relative to the 
wild-type Tf-DT conjugate [46], [47].  
 
Fig 2.6 In vitro cytotoxicity comparisons for CRM107 conjugates. Points, mean from an average of three experiments; 
bars, standard deviation. Wild-type Tf versus K206E/R632A Tf and K206E/R534A Tf in (A, B) U87, (C, D) U251, and 
(E, F) HeLa cells. 
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Cell Line IC50 ± SD (pM) Average IC50 decrease 
associated with mutant Tf 
U87   
Wild-type Tf-CRM107 32.1 ± 3.2  
K206E/R632A Tf-CRM107 7.10 ± 0.87 ~4.6 fold 
K206E/K534A Tf-CRM107 6.80 ± 0.52  
U251   
Wild-type Tf-CRM107 35.3 ± 3.7  
K206E/R632A Tf-CRM107 10.9 ± 1.8 ~3.2 fold 
K206E/K534A Tf-CRM107 11.3 ± 1.2  
HeLa   
Wild-type Tf-CRM107 30.3 ± 3.0  
K206E/R632A Tf-CRM107 9.4 ± 1.0 ~3.0 fold 
K206E/K534A Tf-CRM107 10.2 ± 1.4  
 
Table 2.4 IC50 values of various Tf-CRM107 conjugates in cancerous cell lines. The IC50 values of Tf-CRM107 
conjugates are listed for U87, U251, and HeLa cells. SD, standard deviation. Mutant Tf-CRM107 conjugates exhibit 
improved efficacy compared to wild-type Tf-CRM107 conjugates.   
 
These in vitro results are consistent with our projected trends that mutant Tf conjugates 
have an improved efficacy compared to wild-type Tf conjugates. Our mathematical model of the 
Tf-DT intracellular trafficking pathway thus successfully predicted that (i) mutant Tf-toxin 
conjugates were more effective than wild-type Tf-toxin conjugates, and (ii) the increase in drug 
carrier efficacy for CRM107 conjugates was better than for DT conjugates. These results suggest 
that CRM107 appears to be a more suitable therapeutic agent for our mutant Tf to deliver to cancer 
cells.   
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2.3.2 Tf-DT Mathematical Model Successfully Predicts Selectivity of Mutant Tf-CRM107 
for Cancerous Cells Relative to Non-Neoplastic Cells  
Simulations with our Tf-DT conjugate intracellular trafficking model were performed to 
determine differences in selectivity of the mutant Tf-CRM107 conjugate for cancerous, or 
neoplastic, cells relative to non-neoplastic cells. The predicted trends were then validated with in 
vitro cytotoxicity data.  
To simulate the cancer selectivity of our mutant Tf-CRM107 conjugates, we also ran 
cellular toxicity simulations with varying numbers of TfR receptors. Since TfR is overexpressed 
on malignant cells at 5.4 ´ 105 receptors on the cell surface, we varied the number of initial TfR 
receptors over a range of decreased values to model non-neoplastic cells [2], [43]. The results can 
be found below in Fig 2.7. The simulated IC50 values of mutant Tf-CRM107 in neoplastic cells 
was 8.20 pM, while the simulated values for non-neoplastic cells were 11.5 pM, 16.4 pM, 81.0 
pM, and 144.4 pM for 5.4 ´ 104, 2.97 ´ 104, 5.4 ´ 103, and 2.97 ´ 103 TfR, respectively (Table 
2.5). The results from this in silico study shows the trend that decreasing numbers of TfR (i.e., 
modeling non-neoplastic cells) results in reduced cytotoxicity of our mutant Tf-CRM107 
conjugates. Our model thus predicts that mutant Tf-CRM107 conjugates demonstrate selectivity 
for cancerous cells relative to non-neoplastic cells, and suggests that they could be used as a 
targeted cancer therapeutic agent.   
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Fig 2.7 Cytotoxicity simulation of mutant Tf-CRM107 conjugates against neoplastic and non-neoplastic cells. 
Cytotoxicity curves of neoplastic cells (TfR = 5.4 ´ 104) versus non-neoplastic cells show a trend of reduced 
cytotoxicity with reduced TfR.  
 
TfR Number IC50 (pM) 
Neoplastic cells  
5.4 ´ 105 8.20 
Non-neoplastic cells  
5.4 ´ 104 11.5 
2.97 ´ 104 16.4 
5.4 ´ 103 81.0 
2.97 ´ 103 144.4 
 
Table 2.5 Simulation IC50 values of mutant Tf-CRM107 conjugates in neoplastic versus non-neoplastic cells. Results 
demonstrate that a decreased number of TfR results in an increased IC50 value and reduced cytotoxicity.   
 
These differences between cancerous and non-neoplastic cells were predicted for mutant 
Tf-CRM107 because the conjugates are estimated to associate to a lesser degree with cells that 
have fewer TfR on the surface. Since the binding affinity of CRM107 for DTR is 8,000-fold lower 
than native values and the binding affinity of mutant Tf to TfR remains the same compared to 
native values, the main contribution to internalization of the mutant Tf-CRM107 conjugates is the 
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Tf/TfR pathway [47]. The decreased numbers of TfR on cell surfaces of non-neoplastic cells thus 
results in decreased mutant Tf-CRM107 internalization. Because of this difference in conjugate 
internalization for neoplastic versus non-neoplastic cells, the conjugates were less cytotoxic 
toward and selective against non-neoplastic cells. 
To validate our cytotoxicity simulations of the mutant Tf-CRM107 conjugates in non-
neoplastic cells, in vitro cytotoxicity experiments were performed with two non-neoplastic cell 
types, HUVECs and NHAs. Our results indicated that cancer selectivity can be achieved by our 
CRM107 conjugates due to significantly higher IC50 values observed for all conjugates when 
treating non-neoplastic cells, suggesting a potentially good therapeutic index. As seen in Figs 2.8A 
and B, IC50 values for HUVECs were determined to be 195 ± 30, 147 ± 36 (p = 0.2), and 136 ± 24 
pM (p = 0.06) for wild-type Tf, K206E/R632A Tf, and K206E/K534A Tf, respectively. Similar 
results were obtained with NHAs (Figures 2.8C and D), demonstrating IC50 values of 55.0 ± 9.3, 
32.4 ± 7.4 (p = 0.03), and 38.0 ± 6.8 pM (p = 0.06) for wild-type Tf, K206E/R632A Tf, and 
K206E/K534A Tf, respectively. Compared to the in vitro IC50 values for cancerous cells presented 
in Section 3.1, these values are much higher, confirming our mathematical prediction that our 
mutant Tf-CRM107 conjugates exhibit selectivity for cancerous cells relative to non-neoplastic 
cells. From these results, we can conclude that changing the toxin moiety from DT to CRM107, 
which has an 8,000-fold reduced binding affinity, has a significant contribution to improving the 
selectivity. 
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Fig 2.8 In vitro cytotoxicity comparisons for CRM107 conjugates for non-neoplastic cells. Points, mean from an 
average of three experiments; bars, standard deviation. Wild-type Tf versus K206E/R632A Tf and K206E/R534A Tf 
in (A, B) HUVECs and (C, D) NHAs.  
 
Cell Line IC50 ± SD (pM) 
HUVEC  
Wild-type Tf-CRM107 195 ± 30 
K206E/R632A Tf-CRM107 147 ± 36 
K206E/K534A Tf-CRM107 136 ± 24 
NHA  
Wild-type Tf-CRM107 55.0 ± 9.3 
K206E/R632A Tf-CRM107 32.4 ± 7.4 
K206E/K534A Tf-CRM107 38.0 ± 6.8  
 
Table 2.6 In vitro IC50 values of Tf-CRM107 conjugates with non-neoplastic cells. The IC50 values for mutant 
CRM107 against non-neoplastic cells are much higher than against neoplastic cell lines, suggesting a good therapeutic 
index.  
 
In addition, differences in toxicity between wild-type Tf-CRM107 conjugates and both 
mutant Tf-CRM107 conjugates were significantly diminished in non-neoplastic cell lines. The 
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student’s t-test was used to show that the decrease in IC50 exhibited by both mutant Tf-CRM107 
conjugates compared to the wild-type counterpart was not statistically significant (p > 0.05), with 
the exception of the K206E/R632A Tf-CRM107 conjugate against NHAs. The diminished 
difference in IC50 values was likely due to saturation of TfR with the conjugates. Since normal 
cells are expected to express far fewer TfR, additional recycling capabilities of the mutant 
conjugates become inconsequential in the presence of excess Tf-CRM107 conjugates available to 
bind to the receptors and be internalized.  
 
2.4 Conclusion 
Due to the overexpression of TfR on cancer cells, targeted cancer therapeutics that exploit 
the Tf trafficking pathway is currently being evaluated. Previously, we have used a mathematical 
model of the Tf/TfR pathway to predict that conjugates made with a mutated form of Tf results in 
improved efficacy in cancer cell lines. Though we have previously investigated mutant Tf-DT 
conjugates with success, DT has high toxicity and may exhibit dangerous off-target effects.  
In this work, we proposed the utilization of a mathematical model to evaluate the efficacy 
and selectivity of mutant Tf conjugated to an alternate drug. For this mathematical investigation 
of a novel conjugate, we chose to investigate CRM107, a mutant form of DT. We first extended 
our previously developed Tf/TfR model to include a DT/DTR pathway. We then used our 
mathematical model to evaluate how mutant Tf would improve efficacy compared to wild-type Tf 
when the toxin moiety is changed to CRM107 and whether a mutant Tf-CRM107 conjugate would 
exhibit improved selectivity against non-neoplastic cells while maintaining cytotoxic efficacy 
toward cancerous cells.  
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Through our simulations, we predicted that mutant Tf-CRM107 would outperform wild-
type Tf-CRM107 in terms of efficacy toward cancer cells. We also predicted that switching from 
wild-type Tf to mutant Tf in CRM107 conjugates would drastically improve the efficacy of these 
conjugates due to the absence of the DT/DTR trafficking pathway for CRM107. In addition, this 
increase was predicted to be much greater than the increase associated with switching from wild-
type Tf to mutant Tf in DT conjugates. This predicted trend was confirmed in our in vitro 
investigation of toxicity with the U87 and U251 glioma cell lines, as well as the HeLa cell line.  
We also ran simulations to evaluate the selectivity of this novel mutant Tf-CRM107 
conjugate. The results of our simulation suggested that the cytotoxicity of mutant Tf-CRM107 was 
greater in cancerous cells due to overexpression of TfR on those cells. This predicted trend was 
confirmed, as our measured in vitro IC50 values of CRM107 conjugates with normal cell lines were 
many fold higher than the IC50 values observed with cancerous cell lines. Both our in silico 
simulations and in vitro results suggest a potentially greater therapeutic window for the mutant Tf-
CRM107 conjugates. Furthermore, for the normal cell types (HUVECs and NHAs), the 
cytotoxicity curves of the mutant and wild-type Tf-CRM107 conjugates became similar, attributed 
to the saturation of TfR on the normal cells. 
In summary, our mathematical model predicted that (i) mutant Tf-CRM107 exhibited 
improved efficacy compared to wild-type Tf-CRM107, (ii) this improvement in efficacy was 
greater than that of its DT counterparts, and (iii) mutant Tf-CRM107 exhibits a substantial decrease 
in toxic side effects. These mathematical simulations, which were validated by our in vitro studies, 
altogether indicate that CRM107 would be a more suitable therapeutic agent in combination with 
the mutant Tf in future studies.  
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3.  Investigation of Aqueous Two-Phase Systems (ATPSs) and 
Development of a Housing for Automated Enzymatic Signal Enhancement in 
Paper-Based Immunoassays  
3.1 Introduction 
3.1.1 Motivation and background 
Chlamydia is the most common bacterial sexually transmitted infection worldwide [11]. 
Infection of the bacteria Chlamydia trachomatis (C. trachomatis, CT) causes urethritis in men and 
cervithritis in women [12].  Though easily treated, the infection is largely underdiagnosed, as it is 
asymptomatic for 25% of men and up to 80% of women [13]. In addition, when left untreated, the 
infection can progress to serious health problems such as pelvic inflammatory disease and ectopic 
pregnancy in women [12]. Though tests such as nucleic acid amplification tests can detect CT with 
high sensitivity, they require a long turnaround time, causing potential secondary transmissions to 
occur during this period [11]. Accordingly, there remains a need to develop a rapid and sensitive 
point-of-care (POC) test.  
The lateral-flow immunoassay (LFA) is an inexpensive and rapid paper-based diagnostic 
assay that has the potential to meet the World Health Organization’s ASSURED criteria for POC 
testing [14]. However, despite the many advantages of using LFA over conventional tests, their 
commercial sensitivities remain low [11]. One approach to improving the sensitivity of these tests 
is to enhance the signal and increase the intensity of the signal at the detection zone. Methodologies 
such as enzymatic signal enhancement, silver enhancement, and gold enhancement have been 
studied in the literature [14], [23]–[27]. Fluidic manipulations and controlled delivery of multistep 
assays are thus greatly desired for LFAs to seamlessly integrate these complex systems into the 
LFA, but their fabrication still remain a challenge [24], [28], [29]. 
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Previously, our research group has investigated controlled delivery of biomolecules in 
paper-based assays through the novel use of an aqueous two-phase system (ATPS). ATPSs are 
advantageous for use in an LFA device because they are low-cost, require little extra training, and 
also provide a mild environment for biomolecules. Our laboratory has previously demonstrated 
that ATPSs can be used to improve paper-based immunoassays in two ways. Firstly, our group has 
shown the use of ATPSs to pre-concentrate target biomarkers prior to detection on the LFA and 
improve sensitivity. The sensitivity of LFA can be improved by 10-fold by pre-concentrating the 
target biomarkers to a particular phase and applying the concentrated phase to the LFA [73], [74]. 
Secondly, our laboratory has shown the use of ATPSs to deliver only the concentrated portion to 
the detection zone by modulating its macroscopic phase separation behavior on paper. Our 
research group has  shown that a homogeneous, well-mixed solution containing the ATPS solution 
will phase separate rapidly as it wicks up a paper matrix [22], [75]. By changing the 3D architecture 
of the paper matrix, our lab has shown tunable macroscopic phase separation behavior, such as 
significantly lowering the phase separation time of an ATPS, and changing the length of the 
leading phase [22], [75]. By modulating these factors, our research group has been able to 
demonstrate controlled delivery of biomolecules for the improvement of LFA sensitivity.  
This thesis presents more advanced control of biomolecule delivery in paper-based 
immunoassays and improvement of LFA sensitivity. In this work, we demonstrate (i) the use of an 
ATPS for as an automated, sequential delivery mechanism for signal enhancement reagents, and 
(ii) the development of a casing to achieve consistent flow and conjugate release for this system. 
To our knowledge, this is the first time an ATPS has been used for automated delivery of multiple 
reagents on paper, and the first time a casing has been used to fine-tune ATPS flow on LFA.  
Though there have been attempts to integrate enzymatic signal enhancement techniques in 
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LFA, previous methodologies have been limited and required the use of multiple user steps to 
prevent premature enzymatic signal enhancement. Here, we have circumvented this problem by 
utilizing an ATPS in which an enzyme, conjugated to gold nanoprobes, partition into a phase 
opposite from its substrates. The ATPS used was the polymer-salt system formed by poly(ethylene 
glycol-ran-propylene glycol) (EOPO) and sodium sulfate salt, and the model enzyme-substrate 
system chosen was alkaline phosphatase (ALP) and its substrates nitroblue tetrazolium 5-bromo-
4-chloro-3-idolyphosphate (NBT/BCIP).  
Here, we applied a mixed solution containing ATPS components, CT, gold nanoparticles 
decorated with ALP and antibodies to C. trachomatis (anti-CT-ALP-GNPs), and NBT/BCIP to an 
LFA test. As the ATPS phase separated through the paper matrix, it first delivered the leading 
phase containing the concentrated biomarker and anti-CT-ALP-GNPs. Then, as the second phase 
containing the enzymatic substrates flowed up through the detection zone, ALP that had been 
immobilized on the test line cleaved the substrate and deposited a purple precipitate, thus 
enhancing the signal of the paper-based immunoassay.  
In addition to controlling the delivery time of two different reagents and allowing for 
automated sequential delivery, we have demonstrated fine tuning of fluid flow through the paper 
strip and conjugate release through the development of an acrylic housing. This housing (i) fully 
enclosed the paper test strip to prevent flow inconsistencies from fluctuating humidity and 
evaporation and (ii) provided an optimal amount of pressure on the conjugate pad and sample pad 
wick for sufficient contact and improved fluid flow. The acrylic housing was inexpensive and the 
manufacturing process was facile, which kept the test cost-effective and deliverable to end users 
while improving the performance of the test. 
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The robust, single-step diagnostic platform that was developed demonstrated automated 
and sequential delivery of biomarkers and enzymatic signal enhancement reagents in a consistent 
manner. In the future, this platform technology can be extended to other enzymatic signal 
enhancement systems to transform diagnostic assays for chlamydia and other diseases.  
 
3.2 Materials and Methods 
3.2.1 Preparation of EOPO-salt ATPS 
To prepare the ATPS solution, mixtures of poly(ethylene glycol-ran-propylene glycol) 
(EOPO; MW ~12,000; Sigma-Aldrich, St. Louis, MO) and sodium sulfate salt (Sigma-Aldrich, St. 
Louis, MO) were dissolved in Dulbecco’s phosphate-buffered saline (PBS; Invitrogen, Grand 
Island, NY). A final overall concentration of 15% EOPO and 4% sodium sulfate salt was used for 
the diagnostic test. 
 
3.2.2 Preparation of Anti-CT antibody- and Enzyme- decorated Gold Nanoprobes (anti-
CT-ALP-GNPs) 
To form nanoprobes decorated with ALP, 1 mL of 40 nm gold nanoparticles 
(nanoComposix, San Diego, CA) was adjusted to a pH of 8 using 0.1 M sodium borate. Then, 1 
µg of ALP was added to the gold suspension and incubated for 5 minutes at room temperature. 
Subsequently, 8 µg of antibodies specific to CT (MyBioSource, San Diego, CA) was added and 
incubated for 25 minutes at room temperature. Subsequently, 100 uL of 10% BSA was added and 
incubated for 10 min. The gold nanoprobes decorated with ALP were purified four times by 
centrifuging at 6000 rpm for 6 minutes each.  
 
	 55 
3.2.3 Partitioning of Enzymes and Substrates in ATPS  
In order to visually verify the partitioning of enzymes conjugated to gold nanoprobes in an 
ATPS, 20 µL of anti-CT-ALP-GNPs were added to a 1 mL EOPO/sodium sulfate ATPS. Similarly, 
the partitioning of the substrate NBT was visually verified by adding 6.6 µL of NBT/BCIP to a 1 
mL ATPS. The solutions were vortexed thoroughly and allowed to phase separation at room 
temperature for 30 minutes. Pictures were taken at 20 minutes using a Canon EOS 1000D camera 
(Canon U.S.A., Inc., Lake Success, NY) in a controlled lighting environment. 
 
3.2.4 Preparation of Conjugate Pads with Dehydrated anti-CT-ALP-GNPs 
A suspension of anti-ALP-GNPs containing 1% BSA was spotted onto 3 mm x 10 mm 
fiberglass paper (GE Healthcare Life Sciences, Marlborough, MA). The paper was then vacuum-
dried with a benchtop lyophilizer (Labconco, Kansas City, MO) for 30 minutes until completely 
dry. 
 
3.2.5 Fabrication of acrylic housing 
To fabricate the three-piece acrylic housing, clear sheets of acrylic (McMaster-Carr, Santa 
Fe Springs, CA) were cut with a CO2 laser cutter system (Universal Laser Systems U.S.A., Inc., 
Scottsdale, AZ). The top and bottom pieces consisted of full pieces of acrylic, and the center piece 
was designed with a cutout such that the casing would conform to the test strip dimensions. This 
was mounted on the bottom rectangular piece in order to form a trough to hold the test strip. A 4 
mm x 10 mm foam piece (McMaster-Carr, Santa Fe Springs, CA) was added to the top acrylic 
piece such that it would be placed on the interface between the conjugate pad and the membrane. 
The height of the foam piece was modulated with laser-cut 4 mm x 10 mm sheets of adhesive PET 
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film (Adhesives Research, Glen Rock, PA). In addition, the casing was fabricated in such a way 
that the three pieces held the stacks of the LFA wick together. The pieces of the acrylic housing 
were held together by Scotch double sided tape (3M, St. Paul, MN, USA).  
 
3.2.6 Detection of CT with ATPS-mediated Delivery and Enzymatic Signal Enhancement  
LFA test strips utilizing the sandwich assay format were assembled similarly to previous 
studies [22], [75].  Antibodies specific to CT (MyBioSource, San Diego, CA) were immobilized 
on backed nitrocellulose membrane by striping a solution of the antibodies containing 25% sucrose 
(Sigma-Aldrich, St. Louis, MO). This constituted the test line of the test strip. Protein A (Sigma-
Aldrich, St. Louis, MO) was similarly immobilized to constitute the control line of the test. The 
nitrocellulose membrane was cut into strips 3 mm in width.  
The design of the LFA test strip was modified to include the addition of a vertical paper 
well. This larger wick was composed of four stacks of 7 mm x 10 mm fiberglass paper (GE 
Healthcare Life Sciences, Marlborough, MA). The fiberglass paper was treated by adding a 
solution of 0.1% BSA and 0.001% Tween 20 (Sigma-Aldrich, St. Louis, MO) and vacuum-drying 
with a benchtop lyophilizer (Labconco, Kansas City, MO) for 30 min. A cellulose absorbent pad 
(GE Healthcare Life Sciences, Marlborough, MA) was placed downstream of the nitrocellulose 
membrane. Once assembled, the test strip was enclosed in the custom acrylic housing.  
For detection of CT, 500 µL of a well-mixed ATPS containing CT, NBT, and BCIP were 
added to a well in a 24-well plate (Corning Inc., Corning, NY). The test strip enclosed in the 
custom acrylic housing was then placed in the mixed solution. The fluid was allowed to wick up 
vertically through the wick. Images of the detection region were captured at various time points 
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using a Canon EOS 1000D camera (Canon U.S.A., Inc., Lake Success, NY) in a controlled lighting 
environment.  
 
3.3 Results and Discussion 
3.3.1 Partitioning of Enzyme and Substrate into Different Phases 
Effective separation of enzyme and substrates via partitioning in ATPS was first verified 
using the methods described previously. Anti-CT-ALP-GNPs were large enough to have excluded-
volume interactions with the large EOPO molecules in the top, EOPO-rich phase, and partitioned 
preferentially into the bottom, salt-rich phase. This is shown on the left side of Fig. 3.1 with the 
cherry red-colored anti-CT-ALP-GNPs predominantly in the bottom phase. The hydrophobic 
NBT, on the other hand, partitioned preferentially into the top, EOPO-rich phase due to the relative 
hydrophobicity of that phase. This is shown on the right side of Fig. 3.1 with the yellow NBT 
substrate predominantly in the top phase. By choosing an ATPS in which the enzyme conjugated 
to gold nanoprobes partitioned into a phase opposite from its substrate, we prevented premature 
enzymatic signal enhancement.  
 
3.3.2  Improved Conjugate Release and Background with Development of Acrylic 
Housing 
An acrylic housing was developed for our diagnostic platform that fine-tuned fluid flow 
Fig 3.1 Partitioning of enzyme and substrate in ATPS. Anti-CT-ALP-GNPs 
partitioned preferentially into the bottom, salt-rich phase (left), and NBT 
partitioned preferentially into the top, polymer-rich phase (right), effectively 
preventing premature enzymatic signal enhancement.  
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through the test strip and allowed for consistent release of anti-CT-ALP-GNPs from the conjugate 
pad to allow consistent delivery of nanoprobes to the detection region. This acrylic housing was 
designed in such a way that the test strip would snugly fit in the center of the bottom piece (Fig 
3.2a). The addition of the top piece of the housing would then function to fully enclose the test 
strip from the elements and prevent evaporation effects from changing flow patterns and disrupting 
the controlled delivery of reagents in the paper-based immunoassay. In addition, once the housing 
was closed, it applied light pressure on the many stacks of fiberglass paper that constituted the 
wick, and held together the paper strips. Moreover, the top of the housing was designed with an 
extra extruded foam portion placed in such a way that closing the top piece over the bottom piece 
would exert slight pressure on the test strip at the interface between the conjugate pad and 
membrane (Fig 3.2a). The height of the foam was adjusted such that enough pressure was exerted 
without overexerting pressure and crushing the integrity of the paper. The final design for the 
integrated platform technology is shown in Fig 3.2b.   
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Fig 3.2 Integration of ATPS and casing with the LFA.  
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Controlled pressure on the conjugate pad and wick was shown to benefit the release of 
dehydrated anti-CT-ALP-GNPs from the conjugate pad. After tests were run, images were taken 
of the resulting interface between the conjugate pad and the membrane. When no pressure was 
placed on the conjugate pad, the release of the conjugates during rehydration was incomplete, as 
indicated by dark conjugates stuck at the interface (Fig 3.3a). We hypothesize that a lack of 
pressure and thus lack of proper contact between the conjugate pad and membrane resulted in this 
type of pattern formation.  The poor contact resulted in fluid flow that was too slow, which in turn 
allowed more time for the anti-CT-ALP-GNPs to collect and bind nonspecifically to the edges of 
the paper pad interface between the conjugate pad and membrane. This is corroborated by the 
literature, as housings designed with inconsistent pressure points have been shown to result in 
variations in fluid flow, and thus a consistent design is necessary [76], [77]. Conversely, when a 
proper amount of pressure is placed on the pad to ensure proper contact between the conjugate pad 
and the nitrocellulose membrane, the result was clean, even release of the conjugates (Fig 3.3b). 
By modulating the height of the foam piece on the top part of the housing, we optimized the 
pressure exerted on the interface between the conjugate pad and membrane and consistently 
controlled the fluid flow through that interface.  
 
Furthermore, controlling the environment with the acrylic housing was shown to be 
beneficial toward preventing background on the nitrocellulose membrane detection zone. As 
shown in Fig 3.4a, failure to enclose the test strip results in a dark, streaky background. We 
hypothesized that leaving the test strip open to the air results in greater evaporation from the test 
Fig 3.3 Control of conjugate release from the conjugate pad. The 
release of anti-CT-ALP-GNPs was modified by application of 
conjugate pad pressure. No pressure (a) results in incomplete 
conjugate release, while controlled even pressure (b) results in 
sustained and complete release. 
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strip, which prevents efficient delivery of the anti-CT-ALP-GNPs across the nitrocellulose 
detection zone. This was corroborated by previous studies in the literature, in which evaporation 
had been shown to slow fluid flow [18], [78]. Similar patterns of particle deposition from drying 
effects have been reported in the literature as well [79]–[81]. As the test fluid evaporated during 
the test, anti-CT-ALP-GNPs were deposited nonspecifically on the nitrocellulose membrane rather 
than fully flowing downstream to the absorbent pad. The combined effect was an increase in 
nonspecific signals on the detection zone and a highly noisy background. On the contrary, placing 
the test strip in a controlled environment casing protected the test from significant evaporation and 
resulted in a clean, even background (Fig 3.4b). The fabrication of a consistent acrylic housing for 
this system thus improved delivery of biomolecules in the LFA.   
 
 
3.3.3 Automated sequential delivery of signal enhancement reagents with ATPS 
 Using our optimized system, we achieved automated, sequential delivery of enzymatic 
signal enhancement components in the ATPS. Shown in Fig 3.5 is the detection zone of an LFA 
test run at a concentration of 1 ng/µL of CT with our finalized design over three different time 
points. The start of the test was captured and shown in the left panel of Fig 3.5. At this point, the 
Fig 3.4 Effect of controlled environment on LFA background. Running an LFA test 
without the casing resulted in a streaky background (a), while the use of a custom 
casing to provide a controlled environment resulted in a clean background (b).  
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test was dipped into the sample ATPS solution, and phase separation began through the paper 
wick. No fluid was yet delivered to the detection zone at this point, so no lines were present.  
 During the first delivery phase, the leading salt-rich phase of the ATPS was delivered to 
the detection zone. The end of this first step was captured and shown in the center panel of Fig 
3.5. At this point, there was conjugate binding to the test and control lines, and the color was the 
cherry red of the anti-CT-ALP-GNPs. This indicated that anti-CT-ALP-GNPs were successfully 
delivered to the detection zone. In addition, due to the color of the line, the image indicated that 
no enzymatic signal enhancement had begun at this point, and thus the partitioning of the enzyme 
and its substrates to opposite phases of the ATPS was successful in the integrated paper format.  
During the second delivery phase, the polymer-rich phase of the ATPS was delivered to the 
detection zone. The end of the second ATPS delivery phase was captured at 30 min and is shown 
in the right panel of Fig 3.5. During this delivery phase, the NBT/BCIP in the polymer-rich phase 
were delivered to the detection zone, and the ALP immobilized on the test and control lines cleaved 
the substrates to form a dark purple precipitate. This was deposited at the locations of the test and 
control lines, as shown in the darkened purple lines in the image. Compared to the test line after 
the first delivery step, the resulting test line after the second delivery step is visually much darker, 
indicating successful enzymatic signal enhancement.  
 These results indicated that the integrated platform technology for automated enzymatic 
signal enhancement was successfully achieved. The ATPS successfully partitioned the enzyme 
and substrates into opposite phases and delivered them sequentially to the detection zone, thus 
enhancing the signal intensities at the test and control lines.  
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3.4  Conclusion 
Controlled delivery of biomolecules in paper-based immunoassays is essential for 
achieving multistep LFA and improving sensitivity. In this work, we used an ATPS to automate 
the delivery of enzymatic signal enhancement components to the detection zone of an LFA. The 
enzyme was separated from its substrates through their partitioning behaviors in the ATPS to 
prevent premature enzymatic signal enhancement. Each of the components were then delivered 
sequentially via the ATPS phase separation phenomenon on paper. Furthermore, an acrylic 
housing was fabricated to fully enclose the test strip and minimize evaporation effects, and the 
housing was further modified so that adequate pressure would be generated to make sufficient 
contact between the conjugate pad and membrane. The contact generated a sufficient fluid flow 
path through the paper test strip and allowed for consistent conjugate delivery. With this design, 
our optimized integrated platform technology demonstrated precise control of a multistep 
enzymatic signal enhancement assay in a paper-based diagnostic system. In the future, this 
technology can be extended to other multistep assays to improve the sensitivity of LFA even 
further.    
Fig 3.5 Automated enzymatic signal enhancement over time. 
Signal enhancement reagents were delivered to the detection 
zone in an automated multistep fashion. The detection zone is 
shown before biomolecule delivery (left), after delivery of the 
anti-CT-ALP-GNPs and CT (center), and after delivery of 
enzymatic substrates (right). Darkening of the test lines 
indicates successful implementation of enzymatic signal 
enhancement. 
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